The Genetic Architecture of Biological Age in Nine Human Organ 1

2 **Systems**

- Junhao Wen^{1*}, Ye Ella Tian², Ioanna Skampardoni³, Zhijian Yang³, Yuhan Cui³, Filippos 3
- 4 Anagnostakis⁴, Elizabeth Mamourian³, Bingxin Zhao⁵, Arthur W. Toga⁶, Andrew Zaleskey²,
- Christos Davatzikos³
- 5 6 7 8 9 ¹Laboratory of AI and Biomedical Science (LABS), Stevens Neuroimaging and Informatics Institute, Keck School
- of Medicine of USC, University of Southern California, Los Angeles, California, USA
- ²Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of
- 10 Melbourne, Melbourne, Victoria, Australia
- 11 ³Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated
- 12 Diagnostics (AI²D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- 13 ⁴Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy
- 14 ⁵Department of Statistics and Data Science, University of Pennsylvania, Philadelphia, PA, USA
- 15 ⁶Laboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine
- 16 of USC, University of Southern California, Los Angeles, California, USA
- 17
- 18
- 19 *Corresponding author:
- 20 Junhao Wen, junhaowe@usc.edu
- 21 2025 Zonal Ave, Los Angeles, CA 90033, United States
- 22
- 23 Word counts: 5701 words

24 Abstract

- 25 Understanding the genetic basis of biological aging in multi-organ systems is vital for
- 26 elucidating age-related disease mechanisms and identifying therapeutic interventions. This study
- 27 characterized the genetic architecture of the biological age gap (BAG) across nine human organ
- systems in 377,028 individuals of European ancestry from the UK Biobank. We discovered 393
- 29 genomic loci-BAG pairs (P-value $<5x10^{-8}$) linked to the brain, eye, cardiovascular, hepatic,
- 30 immune, metabolic, musculoskeletal, pulmonary, and renal systems. We observed BAG-organ
- 31 specificity and inter-organ connections. Genetic variants associated with the nine BAGs are
- 32 predominantly specific to the respective organ system while exerting pleiotropic effects on traits
- 33 linked to multiple organ systems. A gene-drug-disease network confirmed the involvement of the
- 34 metabolic BAG-associated genes in drugs targeting various metabolic disorders. Genetic
- 35 correlation analyses supported Cheverud's Conjecture¹ the genetic correlation between BAGs
- 36 mirrors their phenotypic correlation. A causal network revealed potential causal effects linking
- 37 chronic diseases (e.g., Alzheimer's disease), body weight, and sleep duration to the BAG of
- 38 multiple organ systems. Our findings shed light on promising therapeutic interventions to
- 39 enhance human organ health within a complex multi-organ network, including lifestyle
- 40 modifications and potential drug repositioning strategies for treating chronic diseases. All results
- 41 are publicly available at <u>https://labs-laboratory.com/medicine</u>.

42 Main

Biological aging is complex and influenced by many factors, including genetics², environmental 43 44 exposures³, and modifiable lifestyle factors⁴ across multiple organ systems. A comprehensive 45 understanding of the phenotypic landscape and genetic architecture underlying biological aging in multiple human organ systems is paramount in forging the path toward precision medicine⁵, 46 including identifying vulnerability (e.g., smoking) and resilience factors (e.g., physical 47 48 activities). This knowledge can improve our understanding of the underlying mechanisms 49 driving age-related diseases, identify novel therapeutic targets, and develop personalized 50 interventions for maintaining health and functional independence in the aging population.

Previous research efforts have made progress in studying the interconnectedness of multi-51 organ systems in human health^{3,6–13}. In a recent study by McCracken et al., a heart-brain-liver 52 53 axis was studied, highlighting direct and indirect associations among the three organs and their 54 interconnectivity and shared biological pathways¹¹. A recent review highlighted the role of inter-55 organ signals in metabolic control, including the secretion of peptides, small molecules, and lipid 56 mediators by metabolic tissues and the involvement of the central nervous system in 57 coordinating peripheral metabolic functions⁹. Riding the crest of the wave of artificial 58 intelligence (AI), the biomedical community has increasingly adopted the biological age gap

59 (BAG) as a comprehensive biomarker of human aging in multiple human organ systems. 60 Specifically, BAG serves as a quantitative phenotype to capture the disparity between an 61 individual's AI-derived age and chronological age, which can be used to model aging-related 62 normative trajectory at the individual level and holds potential for application in disease 63 populations to capture pertinent pathological processes. For instance, Nie et al. derived the 64 biological age in nine organ systems to predict the possibility of becoming centenarian¹³. In our 65 previous study, Tian et al. derived eight BAGs in eight organ systems, correlating them with 66 cognition, chronic disease, lifestyle factors, and mortality³. We employed a support vector 67 machine in cross-validation to predict BAGs for multiple organ systems (Method 1 for details).

However, genetic determinants and biological pathways that underlie the observed 68 69 heterogeneity of organ-specific BAGs remain elusive. Furthermore, whether chronic diseases 70 and lifestyle factors causally impact the divergence between predicted age and chronological age 71 in these organ systems remains to be established, manifesting as either a younger or older 72 biological age. Our previous genome-wide association study (GWAS) uncovered the genetic 73 heterogeneity of the multimodal brain BAGs using magnetic resonance imaging (MRI) data¹⁴. 74 Expanding on prior research, the current study sought to comprehensively depict the genetic 75 architecture underlying biological aging across nine human organ systems, including the brain, 76 cardiovascular, eye, hepatic, immune, metabolic, musculoskeletal, pulmonary, and renal BAGs. 77 Our overarching hypothesis postulates that the genetic determinants associated with the nine 78 BAGs are not only specific to individual organ systems (i.e., BAG-organ specificity) but also 79 directly or indirectly interconnected with other organ systems (i.e., inter-organ connection). 80 In the current study, we analyzed multimodal data from 377,028 individuals of European 81 ancestry in the UK Biobank study¹⁵ (UKBB) to comprehensively capture the genetic architecture 82 of the nine organ systems (Method 2). First, we used data from 154,774 participants to perform 83 GWAS, gene-level, partitioned heritability, and genetic correlation analyses (Method 3). In our

84 Mendelian randomization analyses, we used 222,254 UKBB participants that did not overlap

85 with the individuals used to compute BAG to avoid potential bias¹⁶. We *i*) identified both

86 previously reported and newly identified genomic loci, *ii*) demonstrated a greater genetic

87 heritability estimate for the brain BAG compared to other organ systems, *iii*) constructed a

- 88 network linking genes, drugs, and diseases for potential drug repurposing, *iv*) confirmed that
- 89 BAG-associated variants and genes exhibit BAG-organ specificity and inter-organ connection,
- 90 and v) established both genetic correlations and causal networks among the nine BAGs, chronic
- 91 diseases, and lifestyle factors. All results, including the GWAS summary statistics, are publicly
- 92 accessible through the MEDICINE (Multi-organ biomEDIcal sCIeNcE) knowledge portal:
- 93 <u>https://labs-laboratory.com/medicine</u>.
- 94
- 95 **Results**

96 Genome-wide associations identify 393 genomic loci associated with the nine biological age

- 97 gaps
- 98 In the European populations, GWAS (**Method 3a**) identified 11, 44, 17, 41, 61, 76, 24, 67, and
- 99 52 genomic loci (P-value $<5x10^{-8}$) significantly associated with the brain, cardiovascular, eye,
- 100 hepatic, immune, metabolic, musculoskeletal, pulmonary, and renal BAGs, respectively (Fig. 1).
- 101 All details of the identified loci are presented in **Supplementary eFile 1**. Manhattan and QQ
- 102 plots are presented in **Supplementary eFigures 1-9** and available in the MEDICINE knowledge
- 103 portal (<u>https://labs-laboratory.com/medicine</u>).
- 104 We estimated the intercept of linkage disequilibrium score regression $(LDSC)^{17}$ for the
- 105 nine main GWAS and obtained intercepts of 0.9989±0.009, 1.0185±0.0099, 0.9926±0.0106,
- $106 \qquad 1.0416 \pm 0.0113, \ 1.0293 \pm 0.0107, \ 1.0308 \pm 0.0124, \ 1.0282 \pm 0.0099, \ 1.0442 \pm 0.0104, \ and \ 1.0416 \pm 0.0104, \ 1.0282 \pm 0.0099, \ 1.0442 \pm 0.0104, \ and \ 1.0416 \pm 0.0104, \ 1.0282 \pm 0.0099, \ 1.0442 \pm 0.0104, \ and \ 1.0416 \pm 0.0104, \ 1.0282 \pm 0.0099, \ 1.0442 \pm 0.0104, \ and \ 1.0416 \pm 0.0104, \ 1.0282 \pm 0.0099, \ 1.0442 \pm 0.0104, \ and \ 1.0416 \pm 0.0104, \ 1.0416 \pm 0.01$
- 107 1.0257±0.0112 for the nine BAGs. All the intercepts were close to 1, indicating no substantial
- 108 genomic inflation in the primary GWAS. Furthermore, we conducted four sensitivity analyses
- 109 (Method 3a) to assess the robustness of the primary nine GWASs on individuals of European
- 110 ancestry (**Supplementary eText 1**). Our GWASs demonstrated robustness in split-sample
- 111 GWAS, with a perfect concordance rate for the sign (+/-) of β values (C- β =1) between the split1
- and split2 GWASs. The two sets of β values were highly correlated (0.90<*r*- β <0.99 for Pearson's *r*) and did not significantly differ (*P*- β >0.48 for two-sample t-test). We compared the GWAS
- results with linear models in PLINK and linear mixed-effect models in fastGWA¹⁸, resulting in a
- perfect concordance for the two sets of β values, as well as very similar LDSC intercept values.
- 116 These findings further support the absence of cryptic population stratification in our primary
- 117 GWASs. Sex-stratified GWASs unveiled distinctive genetic patterns specific to each sex, with
- 118 noteworthy disparities observed in the genetic architecture of the immune BAG (r- β =0.29; P-
- 119 $\beta=0.01; C-\beta=0.55$). Immune responses exhibit sex differences that vary across the lifespan and
- are influenced by age and reproductive status¹⁹. Detailed quantitative information regarding these
- 121 observations can be found in **Supplementary eText 1**, while visual representations of these
- 122 patterns are available in **Supplementary eFigures 5** and 7. Finally, the genetic signals identified
- 123 within non-European populations were less prominent compared to the European GWAS due to 124 the limited sample size, but we found a high concordance between the two sets of β values using
- 125 the three proposed metrics ($0.85 < r \beta < 0.95$; $0.89 < C \beta < 1$; $P \beta > 0.12$). This underscores the
- necessity of expanding sample sizes within underrepresented ethnic groups in future GWAS
 studies. Detailed statistics can be found in Supplementary eFiles 2-5.
- 127 Certain genomic loci exhibited unique associations with individual organs, whereas
- others displayed connections to multiple organ BAGs in close genomic proximity based on their
 cytogenetic position. For instance, the locus on chromosome 6 associated with the hepatic
- (rs62401887, position: 24416482 at 6p22.3), immune (rs80215559, position: 25918225 at

6p22.3), metabolic (rs79220007, position: 26098474 at 6p22.2), musculoskeletal (rs2744575,
position: 24494975 at 6p22.3), pulmonary (rs411535, position: 22061040 at 6p22.3), and renal
BAGs (rs55925606, position: 25878848 at 6p22.2) was close with each other on the human
genome. Bayesian colocalization²⁰ analyses (**Method 3h**) supported two distinct causal SNP
within this locus with the liver and musculoskeletal BAGs. Our results showed a posterior

137 possibility (PP) of two distinct causal variants (PP.H3.ABF=0.744) or one shared causal variant

138 (PP.H4.ABF=0.256) associated with both traits in the *GPLD1* gene, although the PP.H4.ABF

hypothesis did not achieve the suggested threshold $(>0.8)^{20}$. Detailed results are presented in Supplementary eFigure 10. However, note that these loci on chromosome 6 are near the majo

140 **Supplementary eFigure 10**. However, note that these loci on chromosome 6 are near the major 141 histocompatibility complex (MHC) region; further dedicated analyses are needed to understand

142 the underlying genetics across different BAGs (e.g., pleiotropy).

143 Many of these loci were mapped to protein-encoding genes and provided functional

144 insights. For example, the top lead SNP (rs62401887 at 6p22.3) within the locus of the hepatic

145 BAG was mapped to the *MRS2* gene by position (with a deleterious score of 14.89) and

146 expression quantitative trait loci (eQTL, P-value=1.09x10⁻¹⁰) (**Method 3c**), which enables

147 magnesium ion transmembrane transporter activity. We illustrate the regional Manhattan plot for

148 the genomic locus with the highest significance for each organ BAG in **Supplementary eFigure**


149 **11**. For instance, the brain BAG exhibited a highly significant locus (top lead SNP: rs371185851

150 at 17q21.31) with multiple protein-encoding genes, including the widely recognized *MAPT* gene 151 encoding tau protein associated with neurodegenerative diseases, such as Alzheimer's disease

 $(AD)^{21}$. Moreover, the SNPs within this locus included enhancers and transcription start sites


153 specific to brain tissue chromatin states, highlighting their functional relevance in brain-related

154 processes (Supplementary eFigure11a).



155 Figure 1: Genomic loci associated with the nine biological age gaps

156 157



158 European ancestry participants from the UK Biobank cohort. The nine organ systems include the

- 159 brain (*N*=30,108), cardiovascular (*N*=111,543), eye (*N*=36,004), hepatic (*N*=111,543), immune
- 160 (*N*=111,543), metabolic (*N*=111,543), musculoskeletal (*N*=111,543), pulmonary (*N*=111,543),
- and renal (N=111,543) BAGs. 393 genomic loci-BAG pairs were identified using a genome-wide
- 162 P-value threshold $[-log_{10}(P-value) > 7.30]$. For visualization purposes, we denoted the genomic
- 163 loci using their top lead SNPs that are not associated with any clinical traits in the EMBL-EBI
- 164 GWAS Catalog. The anatomical illustration of the human body was created using
- 165 <u>BioRender.com</u>. All analyses used the Genome Reference Consortium Human Build 37
- 166 (GRCh37). We present representative features employed in the calculation of each organ organ's
- 167 BAG. BMI: body mass index; IDP: imaging-derived phenotype; GM: gray matter; WM: white
- 168 matter; FC: functional connectivity; OCT: optical coherence tomography; FVC: forced vital
- 169 capacity; FEV: forced expiratory volume; PEF: peak expiratory flow.
- 170

171 Phenome-wide associations demonstrate organ system specificity and inter-organ

172 connection

173 We aimed to investigate the agreement of the identified genomic loci in existing GWAS

- 174 literature. To this end, we performed a phenome-wide association query in the EMBL-EBI
- 175 GWAS Catalog²² for independent significant SNPs within each locus, considering linkage
- 176 disequilibrium and redundant associations (**Method 3d**).
- 177 This pheno-wide associations query identified 11,709 significant associations between 178 the identified loci in our GWAS and clinical traits in the literature linked to each organ system 179 (i.e., BAG-organ specificity) (Fig. 2a). The genomic loci associated with the brain BAG 180 exhibited the highest proportion of associations (74 out of 173) with traits related to the brain, 181 including imaging-derived phenotypes such as brain volume metrics and white matter 182 microstructure, demonstrated in the keyword cloud presented in Fig. 2a. The brain BAG loci 183 were also largely linked to many other traits related to other organ systems and chronic diseases, 184 evidencing inter-organ connections, including metabolic (N=43/173, e.g., cholesterol levels), 185 lifestyle factor (N=1/173, i.e., alcohol consumption), neurodegenerative traits (N=16/173, e.g., 186 AD), and immune (N=7/173, e.g., lymphocyte count). For the eye BAG loci, most associations
- were found in the eye (N=31/128, e.g., retinal nerve fiber layer thickness) and brain traits (N=6/128, e.g., brain morphology), among others.
- 189 For the seven body organ systems, among the loci associated with the cardiovascular 190 BAG, most associations were observed with cardiovascular traits (319 out of 439), such as 191 systolic/diastolic blood pressure and coronary artery disease. Other associations were found with 192 musculoskeletal (N=30/439), metabolic (N=14/439), immune (N=6/439), renal (N=18/1890), and 193 brain (N=9/439) traits. 376 out of 1853 associations were related to hepatic traits (e.g., blood 194 protein, cirrhosis, and bilirubin) for the hepatic BAG loci. Among the loci associated with the 195 immune BAG, abundant associations were found in metabolic (929 out of 1773), immune 196 (N=244/1773), hepatic (N=149/1853), musculoskeletal (N=57/1853), and cardiovascular traits 197 (N=72/1853). For the metabolic BAG loci, most associations were observed in metabolic traits 198 (3841 out of 4907). We found a significant intertwining of metabolic systems with other organ 199 systems, highlighting inter-organ connections in human metabolic activities. Details of the 200 phenome-wide associations are presented in Supplementary eFile 6. Furthermore, we reported
- 201 the complementary results of this phenome-wide association query using the GWAS $Atalas^{23}$
- 202 platform (Supplementary eText 2 and Supplementary eFile 7).
- 203

204 The SNP-based heritability estimates of the nine biological age gaps

We estimated the SNP-based heritability (h^2) across the nine organ systems using the full sample sizes (**Fig. 2b**) of the nine BAGs. Additionally, the distributions of the magnitude of the β coefficient in GWAS and the allele frequency of the alternative allele (effect allele) are shown in Fig. **2c** and **d**. Notably, the sample sizes of the brain and eye BAGs were much smaller than that of the seven body organ BAGs; the body organ BAGs had the same populations.

210 Upon analyzing the full sample sizes, the estimated h^2 for the brain BAG (0.47\pm0.02) 211 outperformed all other organ systems, followed by the eye (0.38 ± 0.02) , pulmonary (0.36 ± 0.006) , 212 renal (0.31 ± 0.006) , metabolic (0.29 ± 0.006) , cardiovascular (0.27 ± 0.006) , musculoskeletal 213 (0.24 ± 0.006) , hepatic (0.23 ± 0.006) , and immune BAGs (0.21 ± 0.006) (Fig. 2b). All heritability 214 estimates were statistically significant after controlling for multiple comparisons using the 215 Bonferroni correction. This trend persisted when subsampling the population of other BAGs to 216 match that of the brain BAG, with comparable distributions in sex and age (Supplementary 217 eFigure 12a). Detailed results of the h^2 estimate are presented in Supplementary eTable 1a-b. Of note, we employed the GCTA²⁴ software to estimate h^2 , acknowledging that previous 218 research^{25,26} has demonstrated variations in the magnitude of h^2 estimates based on the choice of 219

220 methods.

221 To gain deeper insights into the significant genetic signals in the brain and eye, we 222 conducted a detailed examination of the effect sizes (β coefficient) in the GWAS of the nine 223 BAGs, as the effect size is independent of the sample size. The independent significant SNPs of 224 the brain ($|\beta|=0.062\pm0.013$; [0.0470, 0.093]) and eye ($|\beta|=0.0645\pm0.030$) BAG showed larger 225 mean magnitudes than the seven body organ systems (Fig. 2c). Among the body organ BAGs 226 with the same sample size, the renal BAG showed the largest effect size $(0.023 < |\beta| < 0.306)$. This 227 pattern persisted with the results using the subsampled populations to the brain BAGs, presented 228 in Supplementary eFigure 12b. The full set of statistics (e.g., β coefficient) of the independent 229 significant SNPs is detailed in **Supplementary eFile 5** for the European ancestry GWAS.

230 It is widely recognized that the effect size of common genetic variants tends to increase 231 as the allele frequency decreases^{27,28}. This "inverse relationship" was evidenced by our data 232 using independent significant SNPs from the 9 BAGs (Supplementary eFigure 13); the SNP 233 with a lower allele frequency requires a larger sample size to achieve statistical significance. We 234 then hypothesized that the smaller sample sizes of the brain and eye BAGs enabled us to detect 235 significant variants with a relatively higher allele frequency but could not identify the SNPs with 236 a relatively lower allele frequency associated with the body organ BAGs. As shown in Fig. 2d, 237 we observed that the alternative (effect) allele frequency of the independent significant SNPs 238 associated with the brain and eye BAGs was relatively higher than that of the body organ BAGs. 239 This indicates that larger samples are required for the brain and eye to detect SNP effects with a 240 relatively lower allele frequency. This relationship persisted by subsampling the population of 241 other BAGs to that of the brain BAGs, which is presented in Supplementary eFigure 12c. As 242 expected, the β coefficients derived from the whole samples (N>10k for body organ BAGs) were 243 not significantly different from the results using the brain-BAG comparable down-sampled 244 samples (N=30,108) (Supplementary eTable 2).

Another hypothesis is that the features used to compute the brain and eye BAGs – *in vivo* imaging features – are more heritable than those of the body-organ systems. We compared the genetic structure of the nine BAGs and the individual features used to compute the BAGs. This comparison is crucial for gaining insights into how the choice of predictors impacts the results of BAG GWAS, which, in turn, is fundamental for subsequent analyses related to pleiotropy and


250 trait associations. We first estimated the SNP-based heritability for four pulmonary features and 251 compared these with a set of multimodal brain imaging-derived phenotypes from our previous studies^{14,29–32} using the same GCTA software. We hypothesized that the brain imaging features 252 253 would exhibit a higher degree of heritability than the 4 pulmonary features of the pulmonary 254 BAG (i.e., forced vital capacity, forced expiratory volume, peak expiratory flow, and the ratio of 255 forced expiratory volume to forced vital capacity), supported by the results in Supplementary 256 eTable 1c. We then performed GWAS for the four pulmonary features within the European 257 ancestry populations. The Manhattan and QQ plots are presented in Supplementary eFigure 14. 258 The pulmonary BAG showed high genetic correlations using LDSC with the four pulmonary 259 features (-0.79<gc<0.83, Supplementary eTable 3). Using Bayesian colocalization analysis 260 (Method 3h), we identified 99 potential causal variants (PP.H4.ABF>0.80) between the 261 pulmonary BAG and the four underlying features (Supplementary eFile 8). We showcased one 262 causal variant evidenced at one locus (4q24) between the pulmonary BAG and the FEV/FCV 263 feature (Supplementary eFigure 15). The PP.H4.ABF (0.99) denotes the posterior probability 264 of hypothesis H4, which suggests that both traits share the same causal SNP (rs7664805, mapped 265 gene: NPNT). SNPs in linkage disequilibrium with the causal SNP were previously linked to 266 chronic obstructive pulmonary disease in the GWAS Catalog. To elucidate the genetic overlap at 267 the individual SNP level, we showed the β coefficient of the 48 potential causal variants that

268 passed the genome-wide significance for the pulmonary BAG and at least one pulmonary feature

269 in Supplementary eFigure 16.

270 Figure 2: Phenome-wide associations of the identified genomic loci and SNP-wide

- 271 heritability estimates of the nine biological age gap
- 272



a) Phenome-wide association query of the identified genomic loci in the EMBL-EBI GWAS
 Catalog (query date: 24th April 2023, via FUMA version: v1.5.4) showed an organ-specific and
 inter-organ landscape. By examining the independent significant SNPs considering linkage
 disequilibrium (Method 3d) within each genomic locus, we linked them to various clinical traits.

These traits were categorized into high-level groups encompassing different organ systems, 278 279 neurodegenerative and neuropsychiatric disorders, and lifestyle factors. To visually represent the 280 findings, we generated keyword cloud plots based on the frequency of these clinical traits within 281 each BAG. The length of each rectangle block indicates the number of associations concerning 282 the genomic loci in our analysis and clinical traits in the literature. The individual disease traits 283 were categorized within their respective organ systems. However, this categorization doesn't 284 imply that the sum of these diseases exclusively represents the entirety of the organ system or 285 that these diseases are solely associated with one specific organ system. Additional searches on 286 alternative public GWAS platforms, such as the GWAS Atlas, are provided in **Supplementary** eText 2. b) Brain BAG is more heritable than other organ systems using GCTA²⁴. c) Brain BAG 287 288 showed larger effect sizes of the independent significant SNPs than other organ systems. The 289 kernel density estimate plot shows the distribution of the effect sizes (i.e., the magnitude of the 290 linear regression β coefficients) in the nine GWAS. The white horizontal lines represent the 291 mean effect sizes. d) The distribution of the alternative allele frequency (effect allele) for the 292 nine BAGs. Of note, only independent significant SNPs were shown for each BAG in Figures c-293 d. All results in Figures b-d used the original full sample sizes of the nine BAGs; the brain, eye, 294 and other body organ BAGs have different sample sizes. Error bars represent the standard error 295 of the estimated parameters. Results for Figure b-d using the down-sampled sample sizes 296 (N=30,108 of the brain BAG) are shown in Supplementary eFigure 12. ALT FREQS: allele

- 297 frequency of the alternative (effective) allele.
- 298

299 Genes linked to the nine biological age gaps are implicated in organ system-specific

300 biological pathways


To biologically validate our GWAS findings at the gene level, we performed gene-based
 associations using the MAGMA³³ software based on the full P-value distribution from the
 GWAS of the nine BAGs. The significantly associated genes (Supplementary eFile 9) were
 used for the gene set enrichment analysis (GSEA, Method 3e) to annotate relevant biological
 pathways underlying each organ system (Fig. 3a).

- 306 Genes associated with the cardiovascular BAG were implicated in the insulin-like growth 307 factor II binding (IGF-II) pathway (P-value=7.08x10⁻⁷). Genes associated with the eye BAG
- 308 were enriched in the pathway of forebrain dorsal-ventral pattern (FDVP) formation (P-
- 309 value= 6.46×10^{-7}). Among others, the most significant enrichment result shown in the hepatic
- 310 BAG was the flavonoid glucuronidation pathway (P-value= 1.71×10^{-8}). Genes linked to the
- 311 metabolic BAG displayed enrichment in several pathways, including the flavonoid
- 312 glucuronidation pathway (P-value=2.46x10⁻¹⁵) and triglyceride-rich lipoprotein particle clearance
- 313 pathway (P-value= 3.72×10^{-15}), both of which are implicated in liver function. In addition, the
- neutral lipid metabolic process, regulated by complex pathways featuring lipid metabolism
- enzymes and structural proteins, was also identified. Genes associated with the musculoskeletal
 BAG exhibited enrichment in the gene set in an amplicon at 20g11 (P-value=1.54x10⁻¹⁵), defined
- BAG exhibited enrichment in the gene set in an amplicon at 20q11 (P-value= $1.54x10^{-15}$), defined by a study of copy number alterations conducted on 191 patients with breast tumors³⁴. Genes
- 318 associated with the pulmonary BAG displayed significant enrichment in the pathways of the
- negative regulation biosynthetic process (P-value= 3.72×10^{-10}), consistent with a previous DNA
- 320 methylation analysis of pulmonary function using old-aged Chinese monozygotic twins³⁵. Genes
- 321 associated with the renal BAG were implicated in the xenobiotic glucuronidation pathway (P-

- 322 value=1.56x10⁻⁶). Given that the kidney contains most enzymes metabolizing foreign substances
- 323 (i.e., xenobiotics), it plays a crucial role in the overall metabolism of drugs and other foreign
- 324 compounds within the body (Fig. 3a). Detailed results of GSEA are presented in
- 325 Supplementary eFile 10. Sex-stratified results are presented in Supplementary eFigure 17.
- 326

327 Genes linked to the nine biological age gaps display organ system-specific gene expression

- 328 patterns
- 329 To investigate the gene expression patterns of the significant genes associated with the nine
- BAGs, we performed a tissue-specific gene expression analysis³³ using MAGMA and the GTEx
 RNA-seq dataset³⁶ (Method 3f).
- Across 54 human organ tissues (Fig. 3b), genes associated with the cardiovascular BAG
- exhibited significant overexpression in various heart-related tissues (e.g., the aorta and tibial
- artery) and other organs (e.g., the uterus and colon sigmoid). Genes associated with the hepatic
- BAG were overexpressed in the liver and adipose subcutaneous. Several immune system-related
- tissues showed a high average expression of the genes related to the immune BAG, including the
- 337 spleen, blood, and lymphocytes. Likewise, the genes associated with the metabolic BAG showed
- a high expression level in the liver and intestine critical organs in the metabolic system. The
- 339 genes related to the pulmonary BAG displayed significant overexpression in the esophagus
- 340 gastroesophageal junction, artery, and others. The genes associated with the renal BAG were
- overexpressed in the kidney. Detailed results are presented in **Supplementary eFile 11**. Sex-
- 342 stratified results are presented in **Supplementary eFigure 18**.



343 Figure 3: Gene-level biological pathway annotation and tissue-specific gene expression

344

a) Validation of the nine BAGs in gene set enrichment analyses. Gene set enrichment analyses
were performed using curated gene sets and GO terms from the MsigDB database. b) Validation
of the nine BAGs in gene-property analyses. Gene-property analyses evaluate tissue-specific
gene expressions for the nine BAG-related genes using the full SNP P-values distribution. Only

- 349 significant gene sets are presented after adjusting for multiple comparisons using the Bonferroni
- 350 correction. Abbreviation: EGJ: esophagus gastroesophageal junction.
- 351
- 352

353 Gene-drug-disease network substantiates potentially repositionable drugs for aging-related

354 diseases

We performed a drug target enrichment analysis³⁷ for the genes linked to the nine BAGs in the targeted gene sets of drug categories using the DrugBank database³⁸, thereby constructing a gene-drug-disease network of potentially repositionable drugs (**Method 3g**).

557 gene-drug-disease network of potentially repositionable drugs (Method 3g). The constructed cone drug disease network (Fig. 4) identified significant

The constructed gene-drug-disease network (**Fig. 4**) identified significant interactions between 12 metabolic BAG-linked genes, 46 drugs, and many metabolic disorders encoded in

360 the ICD10 code (E70-E90). For instance, the *PPARD* gene was the target gene of the PPAR- δ

361 agonist (SAR 351034, denoted in Fig. 4), which aimed to improve insulin sensitivity and lipid-362 related activities and battle against inflammation and oxidative stress, serving as actionable drugs

363 for metabolic disorders, diabetes, and kidney and liver injury-related diseases³⁹. Our results

364 showed that genes associated with the metabolic BAG were used to develop drugs treating

365 various other diseases – beyond metabolic disorders – related to multiple organ systems (Fig. 4).

366 These included heart-related diseases (e.g., chronic rheumatic heart diseases for I05-I09) and

367 cerebrovascular disease (I60-I69), although the enrichment did not survive correction for

368 multiple comparisons (**Fig. 4**). For instance, the drug MPSK3169A (clinical trial number:

369 NCT01609140; metabolic BAG linked gene: *PCSK9*) is used to treat cerebrovascular disease and


370 coronary heart disease; T3D-959 (clinical trial number: NCT04251182; pulmonary BAG linked

371 gene: *PPARD*), was a candidate drug targeting AD. Detailed results are presented in

372 Supplementary eFile 12.

The drug-gene-disease network reveals the association between genes related to the metabolic BAG and drugs targeting various chronic diseases. It highlights the importance of the metabolic system in the overall functioning of the human body and the potentials of

- 376 repositioning existing drugs to tackle biological aging.
- 377



379 Figure 4: Gene-drug-disease network of the nine biological age gaps

380

381 The gene-drug-disease network reveals a broad spectrum of gene, drug, and disease interactions

across the nine BAGs, highlighting the metabolic-related genes. The ICD-10 code icons

383 symbolize disease categories linked to the primary organ systems (e.g., G30 for Alzheimer's

disease in the CNS). All presented genes passed the nominal P-value threshold (<0.05) and were

385 pharmaco-genetically associated with drug categories in the DrugBank database; the symbol *

386 indicates gene-drug-disease interactions that survived the Bonferroni correction. Abbreviation:

387 ICD: International Classification of Diseases; EGJ: esophagus gastroesophageal junction.

388

389 Heritability enrichment in different cell types, functional categories, tissue-specific gene

390 expression, and chromatin states

391 To further biologically validate our GWAS findings at the SNP level, we performed partitioned heritability analyses⁴⁰ (Method 3i) to estimate the heritability enrichment of genetic variants 392 related to the nine BAGs concerning three different cell types⁴¹ (i.e., neurons, oligodendrocytes, 393 394 and astrocytes, Fig. 5a), 53 non-tissue-specific functional categories⁴⁰ (Fig. 5b), 205 tissue-395 specific gene expression data³⁶ (Fig. 5c) and 489 tissue-specific chromatin states^{42,43} (Fig. 5d). 396 We found significant heritability enrichment in oligodendrocytes (P-value=0.03), a 397 specific type of neuroglial cells, for the brain BAG. The cardiovascular BAG also exhibited 398 significant heritability enrichment in neurons (P-value=0.01) (Fig. 5a, Supplementary eFile 399 13). Concerning the heritability enrichment in non-tissue-specific functional categories, we 400 exemplified the four highest significant partitioned heritability estimates for each BAG in Fig. 401 **5b**. For the brain BAG, the super-enhancer regions employed 17.16% of SNPs to explain 402 0.47 ± 0.04 of SNP heritability (P-value= 1.80×10^{-11}), and the histone H3 at lysine 9 403 (H3K9ac) regions used 12.61% of SNPs to explain 0.61±0.12 of SNP heritability (P-404 value= 2.96×10^{-4}). For the eye BAG, the super-enhancer regions explained 0.39 ± 0.05 of SNP 405 heritability (P-value=2.12x10⁻⁶) using 16.84% of SNPs. For the hepatic BAG, the H3K9ac 406 regions explained 0.69±0.13 of SNP heritability (P-value=3.60x10⁻⁵) using 12.61% of SNPs. For 407 the immune BAG, the TSS regions (i.e., core promoters) explained 0.37±0.08 of SNP heritability 408 (P-value=1.48x10⁻⁶) using 1.82% of SNPs. The 3.11% of SNPs annotated by the promoter 409 regions explained 0.30 ± 0.08 of SNP heritability (P-value=7.64x10⁻⁴) for the metabolic BAG. For the cardiovascular (enrichment=16.39±2.23; P-value=4.70x10⁻¹¹), musculoskeletal 410 411 $(\text{enrichment}=17.34\pm4.08; \text{P-value}=1.65\times10^{-6})$, pulmonary $(\text{enrichment}=16.82\pm2.51; \text{P-value}=1.65\times10^{-6})$ 412 value= 7.58×10^{-9}), and renal (enrichment= 13.96 ± 1.88 ; P-value= 7.25×10^{-9}) BAGs, the highest 413 heritability enrichment was found in the regions conserved across mammals (Fig. 5b. 414 Supplementary eFile 14). These results suggested disproportionate genomic contributions to the 415 heritability of BAGs from multiple functional categories. 416 In addition, the nine BAGs showed high heritability enrichment in specific tissues 417 corresponding to their organ systems. For example, the cardiovascular BAG showed significant heritability enrichment in multiple tissue types, including the artery (e.g., the aorta: P-418 419 value=1.03x10⁻⁷), myometrium (P-value=1.35x10⁻⁴), and uterus (P-value=2.43x10⁻⁴). Significant 420 heritability enrichment was found in the liver for the hepatic (P-value= 5.60×10^{-9}) and metabolic 421 BAGs (P-value=6.24x10⁻⁹). For the immune BAG, significant heritability enrichment was found 422 in fetal blood tissues (P-value=7.36x10⁻⁹) (Fig. 5c, Supplementary eFile 15). These findings 423 were aligned with the tissue-specific gene expression patterns observed at the gene level (Fig. 424 **3b**). 425 The results from multi-tissue chromatin states-specific data further provide the proof-of-426 concept for the organ-specific heritability enrichment among these nine BAGs. For the brain 427 BAG, significant heritability enrichment was found in multiple brain tissues in the H3K4me3 (e.g., P-value=9.06x10⁻⁵ for the hippocampus), H3K4me1 (e.g., P-value=6.94x10⁻⁵ for the 428 hippocampus), and H3K27ac (e.g., P-value=1.15x10⁻⁵ for the anterior caudate) regions. For the 429 430 cardiovascular BAG, significant heritability enrichment was shown in the right ventricle in the

431 H3K4me3 region (P-value=6.36x10⁻⁵) and the artery aorta in the H3K27ac region (P-

432 value=5.81x10⁻⁷). Significant heritability enrichment was found in primary hematopoietic stem

- 433 cells in the H3K4me1 region for the immune BAG for both females (P-value=5.61x10⁻⁵) and
- 434 males (P-value= 9.50×10^{-5}). The fetal leg muscle tissue in the DNase regions (P-value= 6.54×10^{-5})
- 435 for the musculoskeletal BAG showed significant heritability enrichment. For the pulmonary
- 436 BAG, significant heritability enrichment was found in the fetal lung in the H3K4me1 (P-
- 437 value= 1.33×10^{-9}) and DNase regions (P-value= 3.80×10^{-8}), among other tissues from the
- 438 stomach, artery, and muscle. For the renal BAG, significant enrichment was shown in the liver in
- 439 the H3K9ac region (P-value=2.46x10⁻⁵) and the gastric tissues in the H3K27ac region (P-
- 440 value= 6.24×10^{-5}) (Fig. 5d, Supplementary eFile 16).
- 441 442

443 Cheverud's Conjecture: genetic correlations between the nine biological age gaps mirror

444 their phenotypic correlations

- 445 We estimated the genetic correlation (g_c) (Method 3h) and the phenotypic correlation $(p_c$ for
- 446 Pearson's correlation coefficient) between each pair of the nine BAGs. Our results supported the
- 447 long-standing Cheverud's Conjecture¹ the genetic correlation between two clinical traits 448 reflects their phenetymic correlation (Fig. 5a)
- 448 reflects their phenotypic correlation (Fig. 5e).
- 449 The musculoskeletal and hepatic BAGs showed the highest genetic correlation ($g_c=0.40$)
- 450 and phenotypic correlation ($p_c=0.38$). Similarly, the hepatic and renal BAGs showed a high
- 451 genetic correlation ($g_c=0.39$) and phenotypic correlation ($p_c=0.37$). The musculoskeletal BAG
- 452 also showed significant genetic and phenotypic correlations with pulmonary ($g_c=0.35$, $p_c=0.19$) 453 and renal BAGs ($g_c=0.13$, $p_c=0.21$). In addition, the eye BAG showed small genetic and
- 454 phenotypic correlations with the brain BAG ($g_c=0.15$, $p_c=0.15$). The dutition, the eye BAG showed small genetic and 454 phenotypic correlations with the brain BAG ($g_c=0.15$, $p_c=0.11$). The correlations between the
- brain and eye BAGs and other organ BAGs were relatively weaker than those observed among
- 456 other organ pairs. These findings indicate the presence of shared genetic underpinnings that
- 457 collectively contribute to the biological aging processes captured by these organ BAGs. Most of
- 458 the genetic correlations showed consistency between females and males, albeit sex differences
- 459 were evident in certain BAGs, particularly in the cardiovascular BAG results. Specifically, males
- 460 exhibited dominant correlations between cardiovascular BAGs and hepatic and renal BAGs,
- 461 while females demonstrated unique correlations with musculoskeletal and pulmonary BAGs
- 462 (Supplementary eFigure 19). Sex differences in cardiovascular diseases have been explored in
- 463 prior literature⁴⁴, highlighting the divergent effects of factors associated with both sex and gender
- 464 on the clinical presentations and outcomes of cardiovascular disease. Detailed results are
- 465 presented in **Supplementary eFile 17**.
- 466

467 Genetic correlations between the nine biological age gaps and 41 clinical traits of chronic

468 diseases, cognition, and lifestyle factors

- 469 We also estimated g_c between the nine BAGs and 41 clinical traits to examine their genetic
- 470 correlations. The 41 clinical traits encompassed many common chronic diseases and conditions
- 471 and their disease subtypes^{7,45–48}, cognition (e.g., general intelligence and reaction time, and
- 472 lifestyle factors (e.g., computer use) (**Fig. 5f** and **Supplementary eTable 4**).
- The brain BAG was genetically associated with several brain diseases of the central
- 474 nervous system (CNS) and their subtypes, including AD ($g_c=0.37\pm0.14$) and late-life depression
- 475 (LLD, $g_c=0.25\pm0.07$). Furthermore, we observed significant genetic correlations between the

476 brain BAG and years of education (g_c =-0.14±0.05) and intelligence (g_c =-0.15±0.05). The 477 cardiovascular BAG was positively correlated with stroke ($g_c=0.20\pm0.05$), a significant 478 cardiovascular disease, and was negatively correlated with years of education (g_c =-0.17±0.05). 479 The musculoskeletal BAG was positively correlated with hyperlipidemia ($g_c=0.18\pm0.06$), 480 rheumatoid arthritis ($g_c=0.13\pm0.03$), and Crohn's disease ($g_c=0.19\pm0.06$) and was negatively 481 correlated with atrial fibrillation (g_c =-0.11±0.04), years of education (g_c =-0.21±0.04), and 482 intelligence (g_c =-0.18±0.03). The pulmonary BAG was positively associated with 483 hyperlipidemia ($g_c=0.12\pm0.04$), stroke ($g_c=0.15\pm0.05$), liver fat ($g_c=0.12\pm0.04$), and lung 484 carcinoma ($g_c=0.17\pm0.05$). Finally, the renal BAG was positively correlated with chronic kidney 485 disease ($g_c=0.39\pm0.06$) and atrial fibrillation ($g_c=0.09\pm0.03$). Notably, type 2 diabetes showed 486 abundant positive genetic correlations with multiple BAGs, including the brain, cardiovascular, 487 metabolic, pulmonary, and renal. Detailed results are presented in Supplementary eFile 18. 488 Furthermore, we calculated the genetic correlation between the nine BAGs and longevity⁴⁹ and 489 household income⁵⁰. Our findings indicated that the cardiovascular (g_c =-0.16±0.09) and 490 pulmonary BAG (g_c =-0.12±0.07) exhibited negative associations with longevity, defined as 491 cases surviving at or beyond the age corresponding to the 90th survival percentile; the brain 492 BAG (g_c =-0.21±0.04), musculoskeletal (g_c =-0.29±0.03), and pulmonary BAG (g_c =-0.16±0.03) 493 were negatively genetically correlated with household income. We used GWAS summary statistics from a prior study⁵¹ to detect a significant genetic correlation between the immune 494 495 BAG (g_c =-0.13±0.03), pulmonary BAG (g_c =-0.09±0.03), and telomere length (Supplementary 496 eTable 5). 497 These genetic correlations yield insights into potential shared mechanisms underlying the 498 nine BAGs, their relationships with chronic diseases, particularly AD and type 2 diabetes, and


nine BAGs, their relationships with chronic diseases, particularly AD and type 2 diabetes, and
 cognition. These compelling results prompted us to explore the potential causal effects of these

traits on the nine BAGs. In the subsequent section, we unbiasedly selected 17 clinical traits

501 encompassing chronic diseases, cognition, and lifestyle factors to perform Mendelian

502 randomization (Method 3g).

Figure 5: Partitioned heritability enrichment and genetic correlation of the nine biological
 age gaps



a) Cell type-specific partitioned heritability estimates for neurons, oligodendrocytes, and
 astrocytes. b) Partitioned heritability estimates for the general 53 functional categories. For
 visualization purposes, we only showed the four categories with the highest significant estimates
 for each BAG. The label for 500 denotes a 500-bp window around each of the 24 main

510 annotations in the full baseline model, which prevents a biased estimate inflated by heritability in

- flanking regions⁵². c) Tissue-specific partitioned heritability estimates using gene sets from
- 512 multi-tissue gene expression data. d) Tissue and chromatin-specific partitioned heritability
- 513 estimates using multi-tissue chromatin data. e) Cheverud's Conjecture: the genetic correlation
- between two BAGs (g_c , lower triangle) mirrors their phenotypic correlation (p_c , upper triangle).
- 515 **f**) Genetic correlations between the nine BAGs and 41 clinical traits, including chronic diseases
- 516 and their subtypes involving multiple human organ systems, education, intelligence, and reaction
- 517 time. The symbol * denotes Bonferroni-corrected significance; the absence of * indicates all 518 results remain significant after correction. The standard error of the estimated parameters is
- 518 results remain significant after correction. The standard error of the estimated parameters is 519 presented using error bars. Abbreviation: AD: Alzheimer's disease; ASD: autism spectrum
- presented using error bars. Abbreviation: AD: Alzheimer's disease; ASD: autism spectrum
 disorder; LLD: late-life depression; SCZ: schizophrenia; DB: type 2 diabetes; WMH: white
- 520 disorder, LLD. rate-me depression, SCZ. schizophienia, DB. type 2 diabetes, whith white 521 matter hyperintensity: HDLD: hyperlinidenia. AF: strial fibrillation: DA: rhoumatoid arthritic
- 521 matter hyperintensity; HPLD: hyperlipidemia; AF: atrial fibrillation; RA: rheumatoid arthritis;
- 522 CD: Crohn's disease; CKD: chronic kidney disease.
- 523

524 Hepatic and musculoskeletal biological age gaps are causally associated with each other

- 525 We performed two-sample bi-directional Mendelian randomization for each pair of BAGs by
- 526 excluding overlapping populations to avoid bias¹⁶ (Method 3j). We found that the hepatic and
- 527 musculoskeletal BAGs showed a bi-directional causal relationship [from the hepatic BAG to the
- 528 musculoskeletal BAG: P-value= 9.85×10^{-7} , OR (95% CI) = 1.47 (1.26, 1.71); from the
- 529 musculoskeletal BAG to the hepatic BAG: P-value= 1.54×10^{-8} , OR (95% CI) = 2.78 (1.95, 3.97)]
- 530 (Fig. 6). This causal relationship echoes our genetic correlation results: the musculoskeletal and
- 531 hepatic BAGs showed the highest genetic correlation compared to other organ systems (Fig. 5e).
- 532 Detailed results and sensitivity check results are presented in **Supplementary eFile 19** and 533 Supplementary aFigure 20 and 21
- 533 Supplementary eFigure 20 and 21.
- 534 We performed three additional sensitivity check analyses for this bi-directional causal 535 relationship. First, we reperformed the GWAS for hepatic BAG and musculoskeletal BAG, 536 incorporating weight as a covariate due to its established causal associations with several organ 537 systems (Fig. 6). This analysis reaffirmed this bi-directional causal relationship (Supplementary 538 eText 3A). Furthermore, we performed Mendelian randomization by excluding the common 539 SNP within the APOE gene (rs429358) due to its pleiotropic effects. This analysis underscored 540 the robustness of the potential causal relationship from the hepatic BAG to the musculoskeletal 541 BAG, both with and without including this SNP as an instrumental variable, as elaborated in 542 Supplementary eText 3B. Finally, the latent causal variable (LCV⁵³, Method 3j) model 543 confirmed a partially genetically causal effect from the hepatic BAG to the musculoskeletal
- 544 BAG [genetic causality proportion = 0.75 ± 0.14 , -log₁₀(P-value)=11.0, g_c= 0.41 ± 0.06]
- 545 (Supplementary eTable 6).
- 546
- 547

548 Biological age gaps are causally associated with several chronic diseases, body weight, and

549 sleep duration

- 550 We investigated the bi-directional causal effects between chronic diseases (e.g., AD) and
- 551 lifestyle factors (e.g., sleep duration) and the nine BAGs. We unbiasedly and systematically
- included 17 clinical traits (Method 3j) guided by our genetic correlation results (Fig. 5f). The 17

clinical traits included chronic diseases linked to the brain, cardiovascular, metabolic, digestive,
 renal, and musculoskeletal systems, cognition, and lifestyle factors (Supplementary eTable 7).

555 In the forward Mendelian randomization, we found potential causal effects of AD on the 556 brain [P-value=3.99x10⁻⁸, OR (95% CI) = 1.05 (1.03, 1.06), number of SNPs=10], hepatic [P-557 value= 7.53×10^{-7} , OR (95% CI) = 1.03 (1.02, 1.04), number of SNPs=10], musculoskeletal [Pvalue=1.73x10⁻⁵, OR (95% CI) = 0.98 (0.97, 0.99), number of SNPs=10], and renal [P-558 559 value=5.71x10⁻⁴, OR (95% CI) = 0.98 (0.97, 0.99), number of SNPs=10] BAGs. Body weight 560 showed causal effects on multiple organ systems, including the immune [P-value=8.96x10⁻⁵, OR 561 (95% CI) = 1.08 (1.04, 1.11), number of SNPs=160], musculoskeletal [P-value=4.32x10⁻¹⁵, OR 562 (95% CI) = 0.83 (0.79, 0.86), number of SNPs=160], pulmonary [P-value=3.50x10⁻⁷, OR (95%) CI) = 0.84 (0.79, 0.90), number of SNPs=160], and renal BAGs [P-value=4.53x10⁻¹³, OR (95% 563 564 CI) = 1.18 (1.13, 1.23), number of SNPs=160]. In addition, we also found that Crohn's disease 565 had causal effects on the hepatic BAG [P-value= 3.00×10^{-3} , OR (95% CI) = 1.02 (1.00, 1.03), 566 number of SNPs=77], type 2 diabetes on the metabolic BAG [P-value=9.92x10⁻¹², OR (95% CI) =1.16 (1.09, 1.24), number of SNPs=8], inflammatory bowel disease [P-value=1.42x10⁻³, OR 567 568 (95% CI) = 1.02 (1.00, 1.03), number of SNPs=80] and primary biliary cholangitis [P-569 value= 7.41×10^{-4} , OR (95% CI) = 1.02 (1.00, 1.03), number of SNPs=16] on the musculoskeletal 570 BAG (Fig. 6).


For the inverse Mendelian randomization, we found potential causal effects of the metabolic [P-value= 6.85×10^{-4} , OR (95% CI) = 0.94 (0.91, 0.97), number of SNPs=71] and pulmonary [P-value= 3.79×10^{-5} , OR (95% CI) = 0.84 (0.79, 0.91), number of SNPs=62] BAGs on body weight, the cardiovascular BAG on triglycerides versus lipid ratio in very large very-lowdensity lipoprotein (VLDL) [P-value= 2.14×10^{-4} , OR (95% CI) = 1.09 (1.04, 1.14), number of SNPs=39], and the brain BAG on sleep duration [P-value= 2.61×10^{-3} , OR (95% CI) = 1.09 (1.04,

- 576 SINFS-39], and the orall BAG on sleep duration [F-value-2.01x10⁻⁴, OK (95% CI) = 1.09 (1.04,
 577 1.14), number of SNPs=10] (Fig. 6). Detailed results are presented in Supplementary eFile 20.
 578 We performed several sensitivity analyses (Method 3j) to test the robustness of our
 579 findings. Based on these sensitivity checks, we identified potential outlier instrumental variables
- 580 (IVs, i.e., SNPs) for four Mendelian randomization tests (AD and body weight on
 581 musculoskeletal BAG, Crohn's disease on hepatic BAG, and type 2 diabetes on metabolic BAG)
- in the forward Mendelian randomization and one Mendelian randomization test (metabolic BAG
 on body weight) in the inverse Mendelian randomization. Detailed results of the sensitivity check
- 584 are presented in Supplementary eFigure 22-37 for all significant results. We showcased a 585 detailed analysis of the sensitivity results for the metabolic BAG on body weight in
- detailed analysis of the sensitivity results for the metabolic BAG on body weight in
 Supplementary eText 3C. In summary, the potential causal link from the metabolic BAG to
 body weight remained robust across several sensitivity checks despite the identification of two
- potential outlier instrumental variables, namely, rs117233107 and rs33959228.
- In addition, we used the LCV method and found a partially genetically causal effect from
 longevity (99th survival percentile) to the brain BAG (genetic causality proportion =0.45±0.20,
 P-value=0.04). Importantly, we selected the LCV method over Mendelian randomization
 because of the partial population overlap between the longevity GWAS summary statistics and
 our BAG GWAS summary statistics. The LCV analysis also detected a partially genetically
 causal effect from telomere length to the immune BAG (genetic causality proportion =0.33±0.12,
 P-value=0.0002) and the pulmonary BAG (genetic causality proportion =0.67±0.20, P-
- 596 value= 3.57×10^{-16}) (Supplementary eTable 6).
- 597

598 Figure 6: Causal multi-organ network between the 9 biological age gaps and 17 clinical

599 traits of chronic diseases, lifestyle factors, and cognition

600



601

602 We conducted two sets of Mendelian randomization analyses. Firstly, we examined the causal relationships between each pair of BAGs, excluding overlapping populations. Secondly, we 603 604 investigated the causal associations between the 9 BAGs and the 17 unbiasedly selected clinical 605 traits. Bi-directional analyses, including forward and inverse analyses on the exposure and outcome variables, were performed in all experiments. Significant tests were adjusted for 606 607 multiple comparisons using the Bonferroni correction. Each colored arrow represents a potential 608 causal effect connecting the exposure variable to the outcome variable. The symbol "+" denotes 609 an OR larger than 1, while "-" represents an OR smaller than 1. Detailed OR and 95%CI 610 information can be found in Supplementary eFigure 38 and eFile 19-20. It's crucial to approach 611 the interpretation of these potential causal relationships with caution despite our thorough efforts 612 in conducting multiple sensitivity checks to assess any potential violations of underlying 613 assumptions. Abbreviation: AD: Alzheimer's disease; T2D: type 2 diabetes; PBC: primary 614 biliary cholangitis; CD: Crohn's disease; IBD: inflammatory bowel disease; CI: confidence 615 interval; OR: odds ratio.

617 **Discussion**

618 The current study comprehensively depicts the genetic architecture of common genetic variants 619 on biological aging of nine human organ systems using multimodal data from 377,028 European 620 ancestry participants. We identified many genomic loci for the BAGs of nine human organ 621 systems, which exhibited significant associations with a wide range of clinical traits documented 622 in the GWAS Catalog. These associations were observed within a phenotypic landscape 623 characterized by BAG-organ specificity and inter-organ connections. The brain BAG showed the 624 highest SNP-based heritability estimate among all nine organ systems. GSEA, tissue-specific 625 gene expression patterns, and heritability enrichment results provided additional evidence 626 supporting biological validation for BAG-organ specificity and inter-organ connections. The 627 phenotypic correlation between BAGs was a proxy for their genetic correlation, thereby 628 supporting the long-standing Cheverud's Conjecture. Mendelian randomization demonstrated 629 potential causal relationships between chronic diseases, particularly AD and type 2 diabetes,

630 body weight, sleep duration, and the nine BAGs.

631 Our large-scale multi-organ GWAS significantly expands the current catalog of genetic 632 variants associated with health-related traits. The discovery of these identified genomic loci has 633 significant clinical implications. These findings provide an invaluable foundation to validate 634 genes or regulatory elements, molecular pathways, and biological processes related to the clinical traits and diseases of interest in the current study and future GWAS analyses. Previous GWAS 635 mainly focused on the BAG in one organ system, such as the brain BAG⁵⁴⁻⁵⁷ from imaging-636 637 derived phenotypes. These investigations have largely overlooked the inherent 638 interconnectedness of human organ systems, which are intricately intertwined with distinct axes. 639 Recent studies have identified notable axes, such as the heart-brain-liver¹¹, brain-eye⁵⁸, and 640 brain-heart⁵⁹ axes, highlighting the importance of comprehending these intricate relationships to 641 understand human physiology and health.

642 Our phenome-wide associations validate the pleiotropic effects of the identified genomic loci, influencing various health-related clinical traits in the GWAS Catalog. Our findings also 643 644 highlight BAG-organ specificity and inter-organ connections, further supporting that biological 645 aging is a complex, multifaceted phenomenon. The human brain regulates various physiological 646 processes and maintains homeostasis throughout the body. Consequently, it is unsurprising that 647 the brain exhibits interconnectedness with clinical traits associated with multiple organ systems. 648 The remarkable enrichment of metabolic traits across various organ systems is unsurprising. As a 649 vital metabolic organ, the liver substantially overlaps genetic variants and loci with both the 650 hepatic and metabolic BAGs. Biologically, the liver's metabolic functions are intricately 651 regulated by hormones like insulin and other metabolic regulators¹². Similarly, the interplay 652 between immune and metabolic processes is essential for maintaining overall health and is 653 crucial for the body's ability to respond to pathogens and regulate metabolic homeostasis⁶.

654 We highlighted that the brain BAG is the most heritable among the nine organ systems. 655 Determining the genetic heritability of specific organ systems can be complex as no organ 656 system functions independently, and many diseases or traits involve complex interactions between multiple organ systems, as well as genetic and environmental factors. The brain plays a 657 658 crucial role in developing and functioning various physiological processes across the body. Its 659 intricate structure and diverse cell types render it vulnerable to genetic influences⁶⁰. Therefore, the brain may exhibit higher genetic stability and less environmental variability⁶¹ than other 660 661 organs. The human brain's extensive functional connectivity and intricate networks may also 662 contribute to its higher heritability. These networks facilitate the transmission of genetic

663 information and the propagation of genetic effects across different brain regions³⁰. Lastly,

664 genetic variations shaping the human brain are pleiotropic and influence cognitive abilities,

behavior, and susceptibility to neurological and psychiatric disorders. Collectively, these factors

may contribute to the marked genetic heritability observed in the human brain compared to otherorgan systems.

668 Our gene-level and partitioned heritability analyses further validate our GWAS findings, 669 supporting BAG-organ specificity and inter-organ connections. In GSEA, the genes associated 670 with the cardiovascular BAG were implicated in the IGF-II pathway. IGF-II activates two 671 receptors (IGF-1R and IR-A) to promote cell growth and survival. The IGF signaling pathway is 672 essential for cardiac development in the human heart - the first functional organ to $develop^{62}$. In 673 particular, IGF-II promotes fetal cardiomyocyte proliferation through the tyrosine kinase 674 receptors IGF1R and INSR. Previous research provided appealing evidence on IGF signaling in 675 cardiac regeneration in animal models and induced pluripotent stem cells⁶³. The flavonoid 676 glucuronidation pathway was the most significant enrichment result shown in the hepatic BAG. 677 A previous study demonstrated that procyanidin C1, a flavonoid in grape seed extract, extended 678 the lifespan of mice⁶⁴. Furthermore, ample evidence indicated that natural flavonoids could be 679 potential therapeutic approaches for non-alcoholic fatty liver disease⁶⁵. The metabolites formed 680 through this pathway can also exert effects beyond the liver and impact other organ systems. Our 681 tissue-specific gene expression analyses provided additional support for the biological relevance 682 of our GWAS findings, as the identified genes exhibited specific expression patterns within 683 tissues from the corresponding organ systems.

684 The heritability enrichment analysis further validates the BAG-organ specificity and 685 inter-organ connections by highlighting the disproportional heritability enrichment of genetic 686 variants in different functional categories, cell types, tissues, and chromatin states. The cell type-687 specific enrichment results in the brain (i.e., oligodendrocytes) and cardiovascular (i.e., neurons) 688 BAGs align with previous research. Specifically, Zhao et al. conducted a large-scale GWAS on 689 brain white matter microstructure and found significant heritability enrichment in glial cells, 690 particularly oligodendrocytes³¹, which aligns with our current findings. Our previous multimodal 691 brain BAG GWAS⁵⁴ also confirmed this enrichment in the brain BAG derived from the white 692 matter microstructural features. Similarly, research has revealed the presence of an "intrinsic 693 cardiac nervous system" within the heart, often called the "heart brain." This system consists of 694 around 40,000 neurons similar to those found in the brain, indicating that the heart possesses a 695 distinct nervous system⁶⁶.

696 Our genetic correlation results confirmed that the genetic correlation generally mirrors 697 phenotypic correlations in multi-organ biological age. This suggests that environmental factors 698 likely affect the aging of multiple organ systems in the same direction. Providing evidence for 699 Cheverud's Conjecture can have clinical implications by providing valuable insights into the 700 genetic basis of complex age-related diseases. For instance, by identifying the shared genetic 701 factors underlying multiple age-related diseases, we can target these common pathways to develop novel treatments or repurpose existing drugs⁶⁷ that have proven efficacy in one disease 702 703 or condition for treating others. Moreover, the validation of Cheverud's Conjecture emphasizes 704 the importance of considering the genetic covariance of age-related diseases in clinical practice. 705 It underscores the need for comprehensive genetic assessments and genomic analyses to

⁷⁰⁶ understand disease risk and progression⁶⁸.

We found a bi-directional causal relationship between the hepatic and musculoskeletal
 BAGs. Abundant research has suggested that liver function and metabolic health, particularly

related to glucose and lipid metabolism, can significantly impact musculoskeletal health⁶⁹. This

- 710 inter-organ connection can cause dysregulation of liver metabolism (e.g., non-alcoholic fatty
- 711 liver disease) linked to musculoskeletal disorders, including osteoporosis, sarcopenia, and
- 712 muscle wasting. The musculoskeletal system can also exert an inverse influence on liver
- function. Regular physical activity and muscle strength have been linked to enhanced liver health
- and decreased susceptibility to liver diseases. To further support this, causal effects of primary biliary cholangitis, a chronic liver disease, on elevated musculoskeletal BAG were confirmed in
- biliary cholangitis, a chronic liver disease, on elevated musculoskeletal BAG were confirmed in
 our Mendelian randomization results (Fig. 6). The absence of direct causal relationships between
- the remaining BAGs can be attributed to various factors with potential explanations and
- 717 the remaining BAGS can be attributed to various factors with potential explanations and 718 implications. One possible explanation is that the brain BAG, having the smallest sample size in
- 719 our GWAS (after removing overlapping participants), may be limited in statistical power. In
- addition, this may suggest that various factors, including chronic diseases, environmental
- exposures, and lifestyle choices, influence biological aging in alternative pathways or mediate
- such changes. Thus, understanding the collective contribution of chronic diseases, environmental
 factors, and lifestyle choices is crucial for comprehending the overall aging process and its
- impact on organ health.
- We found that several clinical traits collectively cause organ systems to appear older or younger than their chronological age. For instance, body weight was causally associated with the immune, musculoskeletal, metabolic, and pulmonary BAGs. For several reasons, body weight
- can causally influence multiple organ systems. Excessive body weight (e.g., obesity) has
- metabolic consequences, including increased inflammation, insulin resistance, and dysregulation
- of metabolic pathways in adipose tissue⁷⁰. It also leads to mechanical stress on the body,
- 731 contributing to musculoskeletal strain⁷¹ and cardiovascular workload⁷². Hormonal imbalances⁷³
- and lifestyle factors linked to body weight also influence multi-organ function and the
- development of chronic diseases. Being overweight is also a risk factor for type 2 diabetes,
 which was positively causally associated with metabolic BAG (Fig. 6). AD was causally linked
- which was positively causally associated with metabolic BAG (Fig. 6). AD was causally linked
 to the brain, hepatic, musculoskeletal, and renal BAGs. AD, a neurodegenerative disorder
- 736 primarily affecting the brain, can have causal influences on multiple organ systems. For example,
- 737 it has broader systemic involvement beyond the brain, mediated by mechanisms including
- 737 in this orotation systemic involvement obyond the orani, included by incentations including 738 protein aggregation (e.g., amyloid- β and tau⁷⁴), vascular dysfunction⁷⁵, inflammation⁷⁶, and other
- secondary factors. Protein aggregates can spread to other organs; vascular abnormalities can
- impact blood flow; inflammation can affect distant organ systems; secondary factors, such as
- 741 medication use and lifestyle changes, also contribute.
- 742

743 Limitations

- 744 This study has several limitations. First, the generalizability of genetic findings from European to
- non-European ancestry populations is limited. Future studies can extend their scope to
- encompass a more diverse array of underrepresented ethnicities, a wider range of disease
- cohorts, and individuals of varying ages throughout their entire lifespan. Secondly, it is essential
- to approach the causality results cautiously, considering the assumptions underlying Mendelian randomization. In future studies, more advanced multi-response Mendelian randomization
- randomization. In future studies, more advanced multi-response Mendelian randomization
 methods⁷⁷ should be utilized. Thirdly, despite our efforts of quality check analyses to scrutinize
- our primary GWAS, it's essential to acknowledge that potential ascertainment bias⁷⁸ and
- rou primary GwAS, it's essential to acknowledge that potential ascertainment blas⁷⁰ and rou confounding related to demographic and socioeconomic factors could potentially introduce
- ryptic population stratification, which may not be entirely resolved in the current study. Finally,
- the large number of genomic loci identified in our GWAS may have connections to BAGs due to

various factors, such as biological processes, potential confounding due to demographics, or

specific study design and phenotyping aspects. It's important to note that the effects at these loci

might not be inherently biological but could be influenced by other unmeasured confoundingfactors.

758 i 759

760 **Outlook**

761 In conclusion, our study presents compelling genetic evidence to support that no organ system is

762 $an island^1$ – the collective influence of various chronic diseases on these multi-organ systems

and the interconnectedness among these human organ systems. These findings highlight the

importance of comprehensively understanding the underlying causes of chronic diseases within

the multi-organ network. By shedding light on its comprehensive genetic architecture, our study paves the way for future research to unravel complex disease mechanisms and develop holistic

767 approaches to ameliorate overall organ health.

¹ We adapt the concept of "No Man Is An Island" from the poem by John Donne, highlighting the interconnectedness of human organ systems.

769 Methods

770 Method 1: Support vector machines to predict the chronological age of nine organ systems

Our prior study³ used support vector machines to predict the chronological age of healthy
 individuals – defined as no self-reported and healthcare-documented lifetime chronic medical
 conditions – based on phenotypes from the nine organ systems. Support vector machine

- regression was preferred over linear regression for its enhanced robustness to outliers and
- overfitting. We performed a 20-fold cross-validation procedure and developed predictive models
- 776 for each organ system.
- 777 In each of the 20-fold cross-validation iterations, a linear support vector machine was 778 employed to predict chronological age. The training set consisted of 19 folds of individuals, and 779 the fitted regression coefficients (feature weights) were then applied iteratively to the remaining 780 held-out set (test set) to predict the chronological age of each healthy individual. This approach 781 ensured that the prediction model was not trained using the same individuals for which it made 782 predictions, minimizing the risk of overfitting. Before each iteration of model training, all 783 measures (excluding categorical variables) were standardized using the weighted column mean 784 and standard deviation computed within the training set. The SVM box constraint and kernel 785 scale were set to unity, while the half-width of the epsilon-insensitive band was set to a tenth of 786 the standard deviation of the interquartile range of the predicted variable (chronological age). 787 The SVM was solved using sequential minimal optimization with a gap tolerance of 0.001. The 788 mathematical principles of support vector machines are well-established in the field and have 789 been widely recognized⁷⁹. Further details on this topic can be found in our previous study³.
- 790 The concept of biological age gap derived from artificial intelligence has been widely investigated, especially the brain age^{80,81}. The calculation of the nine BAGs were established in 791 792 our previous works^{3,14}. We previously showed that the prediction accuracy of biological age was 793 not influenced by the number of phenotypes, despite variations across different organ systems. 794 While some prior studies⁸² used deep learning for brain BAG and obtained a lower mean 795 absolute error, we have previously demonstrated that lower mean absolute error might 796 compromise sensitivity to disease-related information⁸³. In our previous GWAS¹⁴, which 797 separately examined three multimodal brain BAGs derived from T1-weighted, diffusion, and 798 resting-state fMRI data, we extensively investigated the influence of various brain imaging 799 feature types and study designs on the genetic signals. Our results unveiled both the consistency 800 and distinctions in the genetic foundations across these diverse contexts. Finally, we recognize 801 that ascertainment bias may be present in our GWAS due to variations in sequencing techniques,
- 802 differences between populations (e.g., disease populations vs. healthy controls), and
- socioeconomic factors that have not been explicitly modeled in our study.
- 804

805 Method 2: Study populations

806 UKBB is a population-based study of approximately 500,000 people recruited between 2006 and
 2010 from the United Kingdom. The UKBB study has ethical approval, and the ethics committee
 808 is detailed here: <u>https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-</u>
 809 <u>advisory-committee</u>.

- 810 The current study analyzed multimodal data, including imaging-derived phenotypes 811 (IDP) and physical and physiological measures in nine human organ systems from 154,774
- 812 UKBB participants. In our previous study, we constructed BAGs for eight organ systems using
- machine learning, including MRI data for brain BAG from 30,108 participants (European

- ancestry), pulse rate and blood pressure data for cardiovascular BAG, liver-related blood
- 815 biomarkers for hepatic BAG, C-reactive protein and blood hematology variables for immune
- 816 BAG, blood biomarkers for metabolic BAG, physical measurements and vitamin D for
- 817 musculoskeletal BAG, lung functioning measurements for pulmonary BAG, and glomerular
- 818 filtration and electrolyte regulation biomarkers for renal BAG from 111,543 participants.
- 819 Furthermore, the current study also used 60 optical coherence tomography (OCT)-derived
- 820 measures from 36,004 participants to derive the BAG of the ninth organ system the eye BAG.
- 821 The inclusion criteria for the features used to predict the eight BAGs, the machine learning 822 methods, and cross-validation procedures are detailed in our previous study³. We initially used
- methods, and cross-validation procedures are detailed in our previous study³. We initially used
 the 88 OCT-derived measures (category ID: 10079) for the additional eye BAG in 67.549
- the 88 OCT-derived measures (category ID: 10079) for the additional eye BAG in 67,549
 participants. Of these measures, 28 were excluded due to a high missing rate (>20% of
- participants). Additionally, 4172 participants were excluded due to a high missing rate (>2070 of 825 participants). Additionally, 4172 participants were excluded due to missing data, and 1798
- 826 participants identified as outliers (outside mean +/- 6SD) for the 60 remaining measures were
- discarded. This finally resulted in 41,966 participants (36,004 European ancestry participants).
- 828 The included 2444 features to derive the BAG of the nine organ systems are presented in

829 Supplementary eFile 21.

In addition, we also performed GWAS for seven variables from 222,254 UKBB participants by excluding the 154,774 participants from the BAG populations to avoid bias due to overlapping samples. These variables included six lifestyle factors and one cognitive variable: N=219,661 (European ancestry) for coffee intake (Field ID:1498), N=221,393 for fresh fruit intake (Field ID:1309), N=221,739 for tea intake (Field ID:1488), N=220,765 for sleep duration (Field ID:1160), N=209,012 for time spent outdoors in summer (Field ID:1050), N=221,337 for body weight (Field ID:21002), and N=220,624 for reaction time (Field ID:20023).

The current work was jointly performed under application numbers 35148 (i.e., genetic data) and 60698 (i.e., the generation of the nine BAGs). In total, we analyzed data from 377,028 individuals of European ancestry in the current study.

840

841 Method 3: Genetic analyses

842 We used the imputed genotype data for all genetic analyses, and our quality check pipeline 843 resulted in 487,409 participants and 6,477,810 SNPs. After merging with the population for each 844 BAG, we included 30,108-111,543 European ancestry participants for the nine BAGs (Fig. 1). 845 To avoid bias due to overlapping populations¹⁶, we also used the rest of the UKBB participants 846 of European ancestry (non-overlapping) to derive the GWAS summary statistics for several 847 lifestyle factors (Method 3i). We summarize the genetic QC pipeline. First, we excluded related 848 individuals (up to 2nd-degree) from the complete UKBB sample using the KING software for 849 family relationship inference.⁸⁴ We then removed duplicated variants from all 22 autosomal chromosomes. Individuals whose genetically identified sex did not match their self-850 851 acknowledged sex were removed. Other excluding criteria were: i) individuals with more than 852 3% of missing genotypes; ii) variants with minor allele frequency (MAF) of less than 1% 853 (dosage mode⁸⁵); iii) variants with larger than 3% missing genotyping rate; iv) variants that 854 failed the Hardy-Weinberg test at 1×10^{-10} . To adjust for population stratification,⁸⁶ we derived 855 the first 40 genetic principle components (PC) using the FlashPCA software⁸⁷. Details of the genetic quality check protocol are described elsewhere^{14,46,88}. Details of the genetic quality check 856 857 protocol are described elsewhere^{29,46}.

859 (a): Genome-wide association analysis: For GWAS, we ran a linear regression using Plink⁸⁹ for 860 each BAG, controlling for confounders of age, dataset status (training/validation/test or 861 independent test dataset), age x squared, sex, age x sex interaction, age-squared x sex interaction, 862 and the first 40 genetic principal components; additional covariates for total intracranial volume 863 and the brain position in the scanner were included for brain BAG GWAS. We adopted the 864 genome-wide P-value threshold (5 x 10⁻⁸) and annotated independent genetic signals considering 865 linkage disequilibrium (see below).

To check the robustness of our GWAS results, we performed several sensitivity check analyses, including *i*) sex-stratified GWAS for males and females, *ii*) split-sample GWAS by randomly dividing the entire population into two splits (sex and age-matched), *iii*) non-European ancestries GWAS, and *iv*) fastGWA for linear mixed effect GWAS, hypothesizing that the main

609 GWASs with European ancestry did not show substantial genomic inflation due to cryptic

871 population stratification. In all our sensitivity check analyses, we considered linkage

872 disequilibrium. We only evaluated the independent significant SNPs of the two sets of β

873 coefficients between splits, genders, ancestry groups, and GWAS methods. The definition of the

874 independent significant SNPs used the same parameters as in FUMA (Supplementary eMethod

1). We used the raw genotype data and the Plink *clump* command (250 kb) and defined a set of

876 SNPs in linkage disequilibrium with the independent significant SNPs – analogous to the

877 candidate SNPs in FUMA.

878

(b): SNP-based heritability: We estimated the SNP-based heritability (h^2) using GCTA²⁴ with the same covariates in GWAS. We reported results from two experiments for each BAG using *i*) the full sample sizes and *ii*) randomly down-sampled sample sizes to that (*N*=30,108) of the brain BAG with comparable distributions regarding sex and age – the sample size of brain BAGs was smaller than the other BAGs.

884

885 (c): Annotation of genomic loci: The annotation of genomic loci and mapped genes was 886 performed via FUMA⁹⁰. For the annotation of genomic loci, FUMA first defined lead SNPs (correlation $r^2 \leq 0.1$, distance < 250 kb) and assigned them to a genomic locus (non-887 888 overlapping); the lead SNP with the lowest P-value (i.e., the top lead SNP) was used to represent 889 the genomic locus in Fig. 1. For gene mappings, three different strategies were considered. First, 890 positional mapping assigns the SNP to its physically nearby genes (a 10 kb window by default). 891 Second, eQTL mapping annotates SNPs to genes based on eQTL associations using the GTEx v8 892 data. Finally, chromatin interaction mapping annotates SNPs to genes when there is a significant 893 chromatin interaction between the disease-associated regions and nearby or distant genes⁹⁰. The 894 definition of top lead SNP, lead SNP, independent significant SNP, and candidate SNP can be 895 found in Supplementary eMethod 1.

896 For the top lead SNP of each identified genomic locus, we showcased whether it was 897 previously associated with any clinical traits considering linkage disequilibrium (5000kb around 898 top lead SNP) in the **EMBL-EBI GWAS** Catalog the platform 899 (https://www.ebi.ac.uk/gwas/home). For instance, we aimed to query the locus with the top lead 900 SNP (rs60569686) associated with the renal BAG. First, we looked up the chromosomal position 901 (i.e., chromosome 13) and found that the location is chr13:49170160 (GRCh38). We then search 902 the GWAS Catalog for a 5000kb region around this top lead SNP: "chr13:49167660-49172660" 903 (https://www.ebi.ac.uk/gwas/regions/chr13:49167660-49172660; query date: 12th October 904 2023). In this region, we discovered no prior associations. It's important to note that this search is

not comprehensive, as new GWAS studies continually emerge on various open platforms, such
 as IEU OpenGWAS⁹¹ (<u>https://gwas.mrcieu.ac.uk/</u>) and GWAS ATLAS²³
 (<u>https://atlas.ctglab.nl/PheWAS</u>).

908

909 (d): Phenome-wide association look-up queries: We first queried the significant independent 910 SNPs within each locus in the EMBL-EBI GWAS Catalog (query date: 24th April 2023, via 911 FUMA version: v1.5.4) to determine their previously identified associations with any other traits 912 (P-value<1x10⁻⁵ by default in the EMBL-EBI GWAS Catalog). For visualization purposes, we 913 further mapped the associated traits into organ-specific groups and other chronic disease traits 914 and cognition. We performed the following procedure to fully consider LD and remove 915 redundant associations among the independent significant SNPs. If the top lead SNP showed any 916 clinical associations, this would present the current locus; if not, we queried the independent 917 significant SNPs (in high correlation with the top lead SNP), starting with the most significant 918 SNPs, until we identified established associations. In this way, only one genetic variant within 919 each genomic locus was considered. We also conducted a complementary phenome-wide 920 association query on the GWAS Atlas platform. We applied the same P-value threshold search 921 criteria as those used in the EMBL-EBI GWAS Catalog. The same procedure, considering 922 linkage disequilibrium and redundant associations, was applied. These exemplary findings are 923 presented as a supplementary search to complement the results shown in Fig. 2a, and are 924 available in Supplementary eText 2.

925

926 (e): Gene set enrichment analysis: We first performed gene-level association analysis using 927 MAGMA³³. First, gene annotation was performed to map the SNPs (reference variant location 928 from Phase 3 of 1,000 Genomes for European ancestry) to genes according to their physical 929 positions. Of note, other advanced annotation methods exist that integrate functional insights, 930 such as brain chromatin interaction⁹² and cell-type-specific gene expression⁹³. We then performed gene-level associations based on the SNP GWAS summary statistics to obtain gene-931 932 level p-values between the nine BAGs and the curated protein-encoding genes containing valid 933 SNPs. We performed GSEA using the gene-level association p-values. Gene sets were obtained 934 from the Molecular Signatures Database (MsigDB, v7.5.1)⁹⁴, including 6366 curated and 10,402 935 ontology gene sets. All other parameters were set by default for MAGMA. The Bonferroni 936 method was used to correct multiple comparisons for all tested gene sets.

937

(f): Tissue-specific gene expression analysis: MAGMA performed gene-property analyses to
identify tissue-specific gene expression of the nine BAGs. The gene-property analysis converts
the gene-level association P-values (above) to Z scores and tests a specific tissue's gene
expression value versus the average expression value across all tissues in a regression model.
Bonferroni correction was performed for all tested gene sets. We reported the results from the 54
tissue types using the GTEx V8 data.

944

945 (g): Gene-drug-disease network: We tested the enrichment of the nine BAG-linked genes in the

targeted gene sets for different drug categories from the DrugBank database³⁸. The gene-drug-

947 disease network was constructed to prioritize potentially repositionable drugs. The GREP

948 software³⁷ performs Fisher's exact tests to examine whether the prioritized genes are enriched in

949 gene sets targeted by drugs in a clinical indication category for a certain disease or condition.

950 Bonferroni correction was performed for all tested drugs.

951

(h): Genetic correlation: We used the $LDSC^{17}$ software to estimate the pairwise genetic 952 953 correlation (g_c) between each pair of BAGs, as well as between the nine BAG and 41 other 954 clinical traits, including chronic diseases involving multiple organ systems, such as AD for brain 955 and chronic kidney disease for kidney, cognition, and lifestyle factors. We used the precomputed 956 LD scores from the 1000 Genomes of European ancestry. To ensure the suitability of the GWAS 957 summary statistics, we first checked that the selected study's population was European ancestry; 958 we then guaranteed a moderate SNP-based heritability h^2 estimate. Notably, LDSC corrects for 959 sample overlap and provides an unbiased estimate of genetic correlation⁶⁸. The inclusion criteria 960 and finally included traits are detailed in Supplementary eTable 3. Bonferroni correction was 961 performed for the 41 clinical traits.

962

963 (i): Partitioned heritability estimate: Our objective is to comprehend how distinct functional 964 genome categories play varying roles in contributing to the heritability of the nine BAGs. 965 Therefore, the partitioned heritability analysis via stratified LD score regression calculates the 966 extent to which heritability enrichment can be attributed to predefined and annotated genome 967 regions and categories⁴⁰. Three sets of functional categories and cell and tissue-specific types 968 were considered. First, the partitioned heritability was calculated for 53 general functional 969 categories (one including the entire set of SNPs). The 53 functional categories are not specific to 970 any cell type and include coding, UTR, promoter and intronic regions, etc. The details of the 53

971 categories are described elsewhere⁴⁰. Subsequently, cell and tissue type-specific partitioned

heritability was estimated using gene sets from Cahoy et al.⁴¹ for three main cell types (i.e.,
astrocyte, neuron, and oligodendrocyte), multi-tissue chromatin states-specific data

973 astrocyte, neuron, and oligodendrocyte), multi-tissue chromatin states-specific data
 974 (ROADMAP⁴² and ENTEx⁴³), and multi-tissue gene expression data (GTEx V8³⁶). Bonferroni

975 correction was performed for all tested annotations and categories. The detailed methodologies

976 for the stratified LD score regression are presented in the original work⁴⁰. The LD scores and

allele frequencies for the European ancestry were obtained from a predefined version based on

- 978 data from the 1000 Genomes project.
- 979

980 (i): Two-sample bi-directional Mendelian randomization: We investigated whether one BAG 981 was causally associated with another BAG and whether the 41 clinical traits were causally 982 associated with the nine BAGs (Fig. 5). To this end, we employed a bidirectional, two-sample 983 Mendelian randomization using the TwoSampleMR package⁹⁵. Both the forward and inverse 984 Mendelian randomization were performed between each pair of traits by switching the exposure 985 and outcome variables. We applied five different Mendelian randomization methods and 986 reported the results of inverse variance weighted (IVW) in the main text and the four others (i.e., 987 Egger, weighted median, simple mode, and weighted mode estimators) in the supplement. 988 Mendelian randomization needs to fulfill several instrumental variable assumptions⁹⁶,

989 including:

990

991

992

- the genotype is associated with the exposure
- the genotype is associated with the outcome through the studied exposure only (exclusion restriction assumption)
- the genotype is independent of other factors that affect the outcome (independence assumption⁹⁷)

We followed a systematic procedure guided by the STROBE-MR Statement⁹⁸ in all steps
 of our causality analyses, including selecting exposure and outcome variables, reporting

997 comprehensive statistics, performing sensitivity checks for potential violations of underlying 998 assumptions, and performing the analyses using alternative methods and software^{53,77}. For the 999 causal inference of each pair of BAGs, all GWAS summary statistics were derived from our 1000 analyses by excluding overlapping populations of the two BAGs. For example, to test the causal 1001 relationship between the brain BAG and cardiovascular BAG, we reran GWAS for the 1002 cardiovascular BAG by excluding the partially overlapping population from the brain BAG. For 1003 all the seven body organ systems that had entirely overlapping populations, we used the GWAS 1004 data from the split-sample analyses (Method 3a). For instance, the GWAS for the cardiovascular 1005 BAG was from the first-split data, and the pulmonary BAG was from the second-split data. 1006 Bonferroni correction was performed for the tested BAGs.

1007 One key challenge in our hypothesis-driven Mendelian randomization is to select these 1008 exposure variables unbiasedly. Clinical traits sharing common genetic covariance with nine 1009 BAGs are more likely to be causally associated with them. We performed a systematic inclusion 1010 procedure using the following criteria to overcome this. We manually queried the 41 clinical 1011 traits – used in our genetic correlation analyses – in the IEU GWAS database, specifically 1012 curated for Mendelian randomization analyses. We ranked all available studies for a certain trait 1013 (e.g., AD) based on the sample sizes. We then chose the study whose populations were of 1014 European ancestry and did not include UKBB participants to avoid bias due to overlapping 1015 populations¹⁶. For the traits whose GWAS data were available in the IEU GWAS database, we 1016 used the TwoSampleMR package to perform the Mendelian randomization analysis. For the 1017 traits whose data were not appropriate in the IEU GWAS database, we then performed another 1018 manual query in the EMBL-EBI GWAS Catalog database to download the available GWAS 1019 summary statistics with the same filter criteria. For the traits whose GWAS data were dominated 1020 by studies using UKBB participants in both databases, we ran GWAS using our own UKBB data 1021 by excluding overlapping populations. Finally, after harmonizing their GWAS summary 1022 statistics (using the function harmonise data from 2SampleMR), this resulted in 17 clinical traits 1023 with at least eight valid IVs (i.e., SNPs). The 17 clinical traits included chronic diseases affecting 1024 multiple organ systems, cognition, and lifestyle factors (Supplementary eTable 7). Bonferroni 1025 correction was performed for all tested clinical traits.

We performed several sensitivity analyses. First, a heterogeneity test was performed to check for violating the IV assumptions. Horizontal pleiotropy was estimated to navigate the violation of the IV's exclusivity assumption⁹⁹ using a funnel plot, single-SNP Mendelian randomization approaches, and Mendelian randomization Egger estimator¹⁰⁰. Moreover, the leave-one-out analysis excluded one instrument (SNP) at a time and assessed the sensitivity of the results to individual SNP.

1032 Following these analyses, we performed three supplementary sensitivity checks for some 1033 specific significant causal signals: i) The exclusion of two common SNPs/IVs (rs429358 and 1034 rs7412) in the APOE gene, considering their potential pleiotropic effects for the hepatic BAG on 1035 musculoskeletal BAG; ii) Incorporating body weight as a covariate in the GWAS for the bi-1036 directional causality between the hepatic BAG and musculoskeletal BAG, as body weight 1037 displayed causal associations with BAGs in multiple organ systems; iii) Re-executing the 1038 Mendelian randomization analysis using alternative software. Specifically, we scrutinized the 1039 causal relationship between the hepatic BAG and musculoskeletal BAG using the latent causal 1040 variance (LCV) model⁵³. Employing different modeling assumptions and instrumental variables 1041 in contrast to Mendelian randomization, it examined the causal relationship between two

1042 interchangeable traits without distinction between the direct and inverse directions. A latent

1043 causal variable (L) acted as a mediator for the genetic correlation between the two traits,

allowing us to quantify the genetic causality proportion (GCP). A positive GCP value between 0

and 1 indicates that trait 1 is partially genetically causal; a negative GCP value means trait 2 is

- 1046 partially genetically causal.
- 1047

1048 (h): Bayesian colocalization: The R package (coloc) was employed to investigate the genetic 1049 colocalization signals between two traits at each genomic locus defined by the pulmonary BAG 1050 GWAS. We employed the Fully Bayesian colocalization analysis using Bayes Factors 1051 (coloc.abf). The method tests five hypotheses, denoted by their posterior probabilities: H0 (no association with either trait), H1 (association with trait 1 but not trait 2), H2 (association with 1052 trait 2 but not trait 1), H3 (association with both traits but with separate causal variants), and H4 1053 1054 (association with both traits with a shared causal variant). It examines the posterior probability 1055 (PP.H4.ABF: Approximate Bayes Factor) to evaluate hypothesis H4, which suggests the 1056 presence of a single shared causal variant associated with both traits within a specific genomic 1057 locus. To determine the significance of the H4 hypothesis, we set a threshold of 1058 PP.H4.ABF>0.8²⁰ and at least 100 SNPs were included within the genomic locus. All other 1059 parameters (e.g., the prior probability of p_{12}) were set as default.

1061 Data Availability

- 1062 The GWAS summary statistics corresponding to this study are publicly available on the
- 1063 MEDICINE knowledge portal (<u>https://labs-laboratory.com/medicine</u>).

1064 Code Availability

1065 The software and resources used in this study are all publicly available:

- MEDICINE: <u>https://labs-laboratory.com/medicine</u>, knowledge portal for dissemination
- BioAge: <u>https://github.com/yetianmed/BioAge</u>, biological age prediction
- PLINK: <u>https://www.cog-genomics.org/plink/</u>, linear model GWAS
- FUMA: <u>https://fuma.ctglab.nl/</u>, gene mapping, genomic locus annotation
- GCTA: <u>https://yanglab.westlake.edu.cn/software/gcta/#Overview</u>, heritability estimates,
 mixed effect GWAS
- 1072 LDSC: <u>https://github.com/bulik/ldsc</u>, genetic correlation, and partitioned heritability
- 1073 TwoSampleMR: <u>https://mrcieu.github.io/TwoSampleMR/index.html</u>, Mendelian
 1074 randomization
- 1075 Coloc: <u>https://github.com/chr1swallace/coloc</u>, Bayesian colocalization
- 1076 LCV: <u>https://github.com/lukejoconnor/LCV</u>, Latent causal variable for causal inference

1077 Competing Interests

1078 None

1080 Authors' contributions

- 1081 Dr. Wen has full access to all the data in the study and takes responsibility for the integrity of the
- 1082 data and the accuracy of the data analysis.
- 1083 Study concept and design: Wen
- 1084 Acquisition, analysis, or interpretation of data: Wen, Tian, Zalesky, Davatzikos
- 1085 Drafting of the manuscript: Wen, Tian, Zalesky, Davatzikos
- 1086 Critical revision of the manuscript for important intellectual content: all authors
- 1087 Statistical analysis: Wen
- 1088 BAG index generation: Tian

1089 **References**

- 1090 1. Cheverud, J. M. A COMPARISON OF GENETIC AND PHENOTYPIC
- 1091 CORRELATIONS. *Evolution* **42**, 958–968 (1988).
- 1092 2. Melzer, D., Pilling, L. C. & Ferrucci, L. The genetics of human ageing. Nat Rev Genet 21,
- 1093 88–101 (2020).
- 1094 3. Tian, Y. E. et al. Heterogeneous aging across multiple organ systems and prediction of
- 1095 chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.
- 1096 4. Cohen, A. A. *et al.* A complex systems approach to aging biology. *Nat Aging* 2, 580–591
 1097 (2022).
- 1098 5. Hodson, R. Precision medicine. *Nature* **537**, S49–S49 (2016).
- 1099 6. Hotamisligil, G. S. Inflammation and metabolic disorders. *Nature* 444, 860–867 (2006).
- 1100 7. Wen, J. et al. Genetic, clinical underpinnings of subtle early brain change along
- 1101 Alzheimer's dimensions. 2022.09.16.508329 Preprint at
- 1102 https://doi.org/10.1101/2022.09.16.508329 (2022).
- 1103 8. Liu, Y. *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI using
 1104 deep learning. *eLife* 10, e65554 (2021).
- 1105 9. Priest, C. & Tontonoz, P. Inter-organ cross-talk in metabolic syndrome. *Nat Metab* 1,
 1106 1177–1188 (2019).
- 1107 10. Jung, J., Zeng, H. & Horng, T. Metabolism as a guiding force for immunity. *Nat Cell Biol*1108 21, 85–93 (2019).
- 1109 11. McCracken, C. *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis in UK
 1110 Biobank participants. *Nat Commun* 13, 7839 (2022).

- 1111 12. Parlakgül, G. et al. Regulation of liver subcellular architecture controls metabolic
- 1112 homeostasis. *Nature* **603**, 736–742 (2022).
- 1113 13. Nie, C. et al. Distinct biological ages of organs and systems identified from a multi-omics
- 1114 study. Cell Reports 38, 110459 (2022).
- 1115 14. Wen, J. et al. The Genetic Heterogeneity of Multimodal Human Brain Age. bioRxiv
- 1116 2023.04.13.536818 (2023) doi:10.1101/2023.04.13.536818.
- 1117 15. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
 1118 *Nature* 562, 203–209 (2018).
- 1119 16. Sanderson, E. et al. Mendelian randomization. Nat Rev Methods Primers 2, 1–21 (2022).
- 1120 17. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from

1121 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).

- 1122 18. Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-scale
 1123 data. *Nat Genet* 51, 1749–1755 (2019).
- 1124 19. Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. *Nat Rev Immunol* 16,
 1125 626–638 (2016).
- 1126 20. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic
- 1127 Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 1128 21. Mummery, C. J. et al. Tau-targeting antisense oligonucleotide MAPTRx in mild
- 1129 Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. *Nat Med* 1–11
- 1130 (2023) doi:10.1038/s41591-023-02326-3.
- 1131 22. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association
- studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* 47, D1005–D1012
- 1133 (2019).

- 1134 23. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex
 1135 traits. *Nat Genet* 51, 1339–1348 (2019).
- 1136 24. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide
- 1137 Complex Trait Analysis. *Am J Hum Genet* **88**, 76–82 (2011).
- Speed, D., Holmes, J. & Balding, D. J. Evaluating and improving heritability models using
 summary statistics. *Nat Genet* 52, 458–462 (2020).
- 1140 26. Evans, L. M. et al. Comparison of methods that use whole genome data to estimate the
- heritability and genetic architecture of complex traits. *Nat Genet* **50**, 737–745 (2018).
- 1142 27. Park, J.-H. et al. Distribution of allele frequencies and effect sizes and their
- 1143 interrelationships for common genetic susceptibility variants. Proc Natl Acad Sci USA
- **108**, 18026–18031 (2011).
- 1145 28. Corte, L., Liou, L., O'Reilly, P. F. & García-González, J. Trumpet plots: visualizing the
- relationship between allele frequency and effect size in genetic association studies.
- 1147 *GigaByte* **2023**, gigabyte89 (2023).
- 1148 29. Wen, J. et al. Genomic loci influence patterns of structural covariance in the human brain.

1149 *Proceedings of the National Academy of Sciences* **120**, e2300842120 (2023).

- 1150 30. Zhao, B. *et al.* Common variants contribute to intrinsic human brain functional networks.
- 1151 Nat Genet 54, 508–517 (2022).
- 1152 31. Zhao, B. *et al.* Common genetic variation influencing human white matter microstructure.
 1153 Science 372, (2021).
- 1154 32. Zhao, B. et al. Genome-wide association analysis of 19,629 individuals identifies variants
- 1155 influencing regional brain volumes and refines their genetic co-architecture with cognitive
- and mental health traits. *Nat Genet* **51**, 1637–1644 (2019).

- 1157 33. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
- 1158 Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).
- 1159 34. Nikolsky, Y. et al. Genome-wide functional synergy between amplified and mutated genes
- 1160 in human breast cancer. *Cancer Res* **68**, 9532–9540 (2008).
- 1161 35. Wang, T. et al. Genome-wide DNA methylation analysis of pulmonary function in middle
- and old-aged Chinese monozygotic twins. *Respir Res* **22**, 300 (2021).
- 1163 36. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580–585 (2013).
- 37. Sakaue, S. & Okada, Y. GREP: genome for REPositioning drugs. *Bioinformatics* 35, 3821–
 3823 (2019).
- 1166 38. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018.
 1167 *Nucleic Acids Res* 46, D1074–D1082 (2018).
- 1168 39. Mittermayer, F. et al. Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative
- 1169 Review of Drugs under Development. *Curr Diabetes Rev* **11**, 17–31 (2015).
- 1170 40. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide
- association summary statistics. *Nat Genet* **47**, 1228–1235 (2015).
- 1172 41. Cahoy, J. D. et al. A Transcriptome Database for Astrocytes, Neurons, and
- 1173 Oligodendrocytes: A New Resource for Understanding Brain Development and Function. J.
- 1174 *Neurosci.* **28**, 264–278 (2008).
- 1175 42. Bernstein, B. E. *et al.* The NIH Roadmap Epigenomics Mapping Consortium. *Nat*
- 1176 *Biotechnol* **28**, 1045–1048 (2010).
- 1177 43. Dunham, I. et al. An integrated encyclopedia of DNA elements in the human genome.
- 1178 *Nature* **489**, 57–74 (2012).

1179 44. Regitz-Zagrosek, V. & Gebhard, C. Gender medicine: effects of sex and gender	1179	44.	Regitz-Zagrosek.	V. & Gebhard	d. C.	Gender medicine:	effects of	sex and gender
---	------	-----	------------------	--------------	-------	------------------	------------	----------------

- 1180 cardiovascular disease manifestation and outcomes. *Nat Rev Cardiol* **20**, 236–247 (2023).
- 1181 45. Hwang, G. et al. Assessment of Neuroanatomical Endophenotypes of Autism Spectrum
- 1182 Disorder and Association With Characteristics of Individuals With Schizophrenia and the
- 1183 General Population. *JAMA Psychiatry* (2023) doi:10.1001/jamapsychiatry.2023.0409.
- 1184 46. Wen, J. et al. Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
- 1185 Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry*
- 1186 (2022) doi:10.1001/jamapsychiatry.2022.0020.
- 1187 47. Yang, Z. et al. A deep learning framework identifies dimensional representations of
- 1188 Alzheimer's Disease from brain structure. *Nat Commun* **12**, 7065 (2021).
- 1189 48. Chand, G. B. et al. Schizophrenia Imaging Signatures and Their Associations With
- Cognition, Psychopathology, and Genetics in the General Population. *Am J Psychiatry* 179,
 650–660 (2022).
- 1192 49. Deelen, J. *et al.* A meta-analysis of genome-wide association studies identifies multiple
 1193 longevity genes. *Nat Commun* 10, 3669 (2019).
- 1194 50. Hill, W. D. *et al.* Genome-wide analysis identifies molecular systems and 149 genetic loci
 1195 associated with income. *Nat Commun* 10, 5741 (2019).
- 1196 51. Codd, V. *et al.* Polygenic basis and biomedical consequences of telomere length variation.
 1197 *Nat Genet* 53, 1425–1433 (2021).
- 1198 52. Gusev, A. et al. Partitioning Heritability of Regulatory and Cell-Type-Specific Variants
- across 11 Common Diseases. *The American Journal of Human Genetics* **95**, 535–552
- 1200 (2014).

- 1201 53. O'Connor, L. J. & Price, A. L. Distinguishing genetic correlation from causation across 52
- 1202 diseases and complex traits. *Nat Genet* **50**, 1728–1734 (2018).
- 1203 54. Wen, J. et al. The Genetic Heterogeneity of Multimodal Human Brain Age.
- 1204 2023.04.13.536818 Preprint at https://doi.org/10.1101/2023.04.13.536818 (2023).
- 1205 55. Ning, K. *et al.* Improving brain age estimates with deep learning leads to identification of
- novel genetic factors associated with brain aging. *Neurobiology of Aging* **105**, 199–204
- 1207 (2021).
- 1208 56. Jonsson, B. A. *et al.* Brain age prediction using deep learning uncovers associated sequence
 1209 variants. *Nat Commun* 10, 5409 (2019).
- 1210 57. Smith, S. M. *et al.* Brain aging comprises many modes of structural and functional change
 1211 with distinct genetic and biophysical associations. *eLife* 9, e52677.
- 1212 58. London, A., Benhar, I. & Schwartz, M. The retina as a window to the brain—from eye
 1213 research to CNS disorders. *Nat Rev Neurol* 9, 44–53 (2013).
- 1214 59. Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic
 1215 resonance images. *Science* 380, abn6598 (2023).
- 1216 60. Zatorre, R. J., Fields, R. D. & Johansen-Berg, H. Plasticity in gray and white: neuroimaging
 1217 changes in brain structure during learning. *Nat Neurosci* 15, 528–536 (2012).
- 1218 61. Tooley, U. A., Bassett, D. S. & Mackey, A. P. Environmental influences on the pace of
 1219 brain development. *Nat Rev Neurosci* 22, 372–384 (2021).
- 1220 62. Díaz Del Moral, S., Benaouicha, M., Muñoz-Chápuli, R. & Carmona, R. The Insulin-like
- 1221 Growth Factor Signalling Pathway in Cardiac Development and Regeneration. *Int J Mol Sci*
- 1222 **23**, 234 (2021).

- 1223 63. Shen, H. et al. Mononuclear diploid cardiomyocytes support neonatal mouse heart
- regeneration in response to paracrine IGF2 signaling. *Elife* **9**, e53071 (2020).
- 1225 64. Xu, Q. et al. The flavonoid procyanidin C1 has senotherapeutic activity and increases
- 1226 lifespan in mice. *Nat Metab* **3**, 1706–1726 (2021).
- 1227 65. Tan, P., Jin, L., Qin, X. & He, B. Natural flavonoids: Potential therapeutic strategies for
- 1228 non-alcoholic fatty liver disease. *Front Pharmacol* **13**, 1005312 (2022).
- 1229 66. Litviňuková, M. et al. Cells of the adult human heart. Nature 588, 466–472 (2020).
- 1230 67. Ballard, C. et al. Drug repositioning and repurposing for Alzheimer disease. Nat Rev
- 1231 *Neurol* **16**, 661–673 (2020).
- 1232 68. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
 1233 *Nat Genet* 47, 1236–1241 (2015).
- 1234 69. Okun, J. G. *et al.* Liver alanine catabolism promotes skeletal muscle atrophy and

1235 hyperglycaemia in type 2 diabetes. *Nat Metab* **3**, 394–409 (2021).

- 1236 70. Barsh, G. S., Farooqi, I. S. & O'Rahilly, S. Genetics of body-weight regulation. *Nature*1237 404, 644–651 (2000).
- 1238 71. Anandacoomarasamy, A., Caterson, I., Sambrook, P., Fransen, M. & March, L. The impact
 1239 of obesity on the musculoskeletal system. *Int J Obes* 32, 211–222 (2008).
- 1240 72. Van Gaal, L. F., Mertens, I. L. & De Block, C. E. Mechanisms linking obesity with
- 1241 cardiovascular disease. *Nature* **444**, 875–880 (2006).
- 1242 73. Stanikova, D. *et al.* Testosterone imbalance may link depression and increased body weight
 1243 in premenopausal women. *Transl Psychiatry* 9, 1–12 (2019).
- 1244 74. Fyfe, I. Influence of amyloid-β on tau spread in Alzheimer disease explained. *Nat Rev*
- 1245 *Neurol* **18**, 318–318 (2022).

- 1246 75. Barisano, G. et al. Blood-brain barrier link to human cognitive impairment and
- 1247 Alzheimer's disease. *Nat Cardiovasc Res* 1, 108–115 (2022).
- 1248 76. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial
- 1249 response? *Nat Med* **12**, 1005–1015 (2006).
- 1250 77. Zuber, V. et al. Multi-response Mendelian randomization: Identification of shared and
- distinct exposures for multimorbidity and multiple related disease outcomes. Am J Hum
- 1252 *Genet* **110**, 1177–1199 (2023).
- 1253 78. Xue, A. *et al.* Genome-wide analyses of behavioural traits are subject to bias by misreports
 1254 and longitudinal changes. *Nat Commun* 12, 20211 (2021).
- 1255 79. Chang, C.-C. & Lin, C.-J. LIBSVM: A library for support vector machines. *ACM Trans.*1256 *Intell. Syst. Technol.* 2, 1–27 (2011).
- 1257 80. Cole, J. H., Marioni, R. E., Harris, S. E. & Deary, I. J. Brain age and other bodily 'ages':
 1258 implications for neuropsychiatry. *Mol Psychiatry* 24, 266–281 (2019).
- 1259 81. Jones, D. T., Lee, J. & Topol, E. J. Digitising brain age. *The Lancet* **400**, 988 (2022).
- 1260 82. Peng, H., Gong, W., Beckmann, C. F., Vedaldi, A. & Smith, S. M. Accurate brain age
- prediction with lightweight deep neural networks. *Medical Image Analysis* 68, 101871
 (2021).
- 1263 83. Bashyam, V. M. *et al.* MRI signatures of brain age and disease over the lifespan based on a
- deep brain network and 14 468 individuals worldwide. *Brain* 143, 2312–2324 (2020).
- 1265 84. Manichaikul, A. et al. Robust relationship inference in genome-wide association studies.
- 1266 *Bioinformatics* **26**, 2867–2873 (2010).
- 1267 85. Zheng, J., Li, Y., Abecasis, G. R. & Scheet, P. A comparison of approaches to account for
- 1268 uncertainty in analysis of imputed genotypes. *Genet Epidemiol* **35**, 102–110 (2011).

- 1269 86. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population
- 1270 stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).
- 1271 87. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-
- scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).
- 1273 88. Wen, J. et al. The Genetic Architecture of Biological Age in Nine Human Organ Systems.
- *medRxiv* 2023.06.08.23291168 (2023) doi:10.1101/2023.06.08.23291168.
- 1275 89. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
 1276 Linkage Analyses. *Am J Hum Genet* 81, 559–575 (2007).
- 1277 90. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- 1278 annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 1279 91. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. 2020.08.10.244293

1280 Preprint at https://doi.org/10.1101/2020.08.10.244293 (2020).

- 1281 92. Sey, N. Y. A. et al. A computational tool (H-MAGMA) for improved prediction of brain-
- disorder risk genes by incorporating brain chromatin interaction profiles. *Nat Neurosci* 23,
 583–593 (2020).
- 1284 93. Weeks, E. M. *et al.* Leveraging polygenic enrichments of gene features to predict genes
 1285 underlying complex traits and diseases. *Nat Genet* 55, 1267–1276 (2023).
- 1286 94. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for
- 1287 interpreting genome-wide expression profiles. *Proceedings of the National Academy of*
- 1288 Sciences 102, 15545–15550 (2005).
- 1289 95. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the
 human phenome. *eLife* 7, e34408 (2018).

- 1291 96. Burgess, S. *et al.* Guidelines for performing Mendelian randomization investigations:
- 1292 update for summer 2023. *Wellcome Open Res* **4**, 186 (2019).
- 1293 97. de Leeuw, C., Savage, J., Bucur, I. G., Heskes, T. & Posthuma, D. Understanding the
- assumptions underlying Mendelian randomization. *Eur J Hum Genet* **30**, 653–660 (2022).
- 1295 98. Skrivankova, V. W. et al. Strengthening the Reporting of Observational Studies in
- 1296 Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326,
- 1297 1614–1621 (2021).
- 1298 99. Bowden, J. et al. A framework for the investigation of pleiotropy in two-sample summary
- 1299 data Mendelian randomization. *Stat Med* **36**, 1783–1802 (2017).
- 1300 100. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
- 1301 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*
- **44**, 512–525 (2015).
- 1303

1304

Acknowledgments 1305

1306 The primary funding support for this present study is from the initial funding package provided

- 1307 by the University of Southern California for WJ. We want to express our sincere gratitude to the
- 1308 UK Biobank team for their invaluable contribution to advancing clinical research in our field.
- 1309 This study used the UK Biobank resource under Application Numbers: 35148 and 60698.
- 1310 Furthermore, we acknowledge the collaborative effort between the University of Southern
- 1311 California, the University of Pennsylvania, and the University of Melbourne in conducting this
- research. We gratefully acknowledge the support of the iSTAGING consortium, funded by the 1312 1313
- National Institute on Aging through grant RF1 AG054409 at the University of Pennsylvania
- 1314 (CD). We also acknowledge the funding provided by the National Institute of Biomedical 1315 Imaging and Bioengineering at the University of Southern California through grant
- 1316 5P41EB015922-25 (AT). Additionally, we acknowledge the funding program from the Rebecca
- 1317 L. Cooper Foundation at the University of Melbourne (AZ). Lastly, WJ would like to thank Paraskevi Parmpi and Jessica Incmikoski for their valuable administrative support during his 1318
- 1319 postdoctoral research at AIBIL. We thank Dr. Joris Deelen and Dr. Joanne M. Murabito for their
- 1320 generosity in providing the GWAS summary statistics from their research⁴⁹ during the revision
- 1321 process. Finally, we thank Caroline O'Driscoll and Ragini Jain for their contribution to
- 1322 developing the MEDICINE knowledge portal.